



Review

Renal Cell Carcinoma as a Metabolic Disease: An Update on Main Pathways, Potential Biomarkers, and Therapeutic Targets

Nicola Antonio di Meo ¹, Francesco Lasorsa ¹, Monica Rutigliano ¹, Davide Loizzo ¹, Matteo Ferro ², Alessandro Stella ³, Cinzia Bizzoca ⁴, Leonardo Vincenti ⁴, Savio Domenico Pandolfo ⁵, Riccardo Autorino ⁵, Felice Crocetto ⁶, Emanuele Montanari ⁷, Marco Spilotros ¹, Michele Battaglia ¹, Pasquale Ditunno ¹ and Giuseppe Lucarelli ^{1,*}

¹ Urology, Andrology and Kidney Transplantation Unit, Department of Emergency and Organ Transplantation, University of Bari "Aldo Moro", 70124 Bari, Italy

² Division of Urology, European Institute of Oncology, IRCCS, 20141 Milan, Italy

³ Laboratory of Human Genetics, Department of Biomedical Sciences and Human Oncology, University of Bari "Aldo Moro", 70124 Bari, Italy

⁴ Division of General Surgery, Polyclinic Hospital, 70124 Bari, Italy

⁵ Division of Urology, VCU Health, Richmond, VA 23298, USA

⁶ Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples "Federico II", 80131 Naples, Italy

⁷ Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy

* Correspondence: giuseppe.lucarelli@inwind.it or giuseppe.lucarelli@uniba.it

Citation: di Meo, N.A.; Lasorsa, F.; Rutigliano, M.; Loizzo, D.; Ferro, M.; Stella, A.; Bizzoca, C.; Vincenti, L.; Pandolfo, S.D.; Autorino, R.; et al. Renal Cell Carcinoma as a Metabolic Disease: An Update on Main Pathways, Potential Biomarkers, and Therapeutic Targets. *Int. J. Mol. Sci.* **2022**, *23*, 14360. <https://doi.org/10.3390/ijms232214360>

Academic Editor: Cristina Peña

Received: 14 September 2022

Accepted: 15 November 2022

Published: 18 November 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: Clear cell renal cell carcinoma (ccRCC) is the most frequent histological kidney cancer subtype. Over the last decade, significant progress has been made in identifying the genetic and metabolic alterations driving ccRCC development. In particular, an integrated approach using transcriptomics, metabolomics, and lipidomics has led to a better understanding of ccRCC as a metabolic disease. The metabolic profiling of this cancer could help define and predict its behavior in terms of aggressiveness, prognosis, and therapeutic responsiveness, and would be an innovative strategy for choosing the optimal therapy for a specific patient. This review article describes the current state-of-the-art in research on ccRCC metabolic pathways and potential therapeutic applications. In addition, the clinical implication of pharmacometabolomic intervention is analyzed, which represents a new field for novel stage-related and patient-tailored strategies according to the specific susceptibility to new classes of drugs.

Keywords: renal cell carcinoma; metabolomics; metabolism; Warburg effect; biomarker

1. Introduction

Renal cell carcinoma (RCC) is among the top 10 malignancies affecting adults globally. Statistical reports estimated that in 2022, 79,000 new cases will be diagnosed, and 13,920 patients will die of kidney cancer in the USA [1].

Clear cell renal cell carcinoma (ccRCC) is the most frequent histological kidney cancer subtype, accounting for more than 75% of all RCC cases [2]. RCC derives its "clear cell" name from the histological appearance of cells, which consists of thin-walled cells filled with abundant lipids and glycogen. In the early stages, this disease is frequently asymptomatic, and incidentally, diagnosed by imaging, having a good prognosis. Conversely, ccRCC has a high mortality rate in the advanced stage due to poor responses to radiotherapy and chemotherapy [3–5]. Over the last decade, significant progress has been made in identifying the genetic alterations driving ccRCC development [6,7]. High-throughput sequencing databases such as the Catalogue of Somatic Mutations in Cancer (COSMIC) and The Cancer Genome Atlas (TCGA) project provided a clear overview of the genes frequently mutated in ccRCC [8,9]. In particular, a total of 13 RCC predisposing

genes (VHL, MET, BAP1, TFE3, TFEF, FLCN, MITF, FH, SDHB, SDHC, SDHD, TSC1, and TSC2) have been identified through studies of hereditary kidney cancer syndromes. Other genes significantly mutated in sporadic ccRCC, in addition to VHL, include PBRM1, SETD2, and KDM5C [10–23]. Interestingly, these three genes encode for proteins with an important role in the maintenance and remodeling of chromatin states. The initiation and development of ccRCC are, in fact, closely related to genomic alterations by epigenetic modification, such as DNA methylation, noncoding RNAs, and post-translational histone modifications.

Furthermore, it has been made clear that epigenetic changes affect the metabolic shift in ccRCC and that, in turn, metabolic intermediates may have an impact on how the genome is expressed during ccRCC progression. A recent study showed that RCC significantly overexpressed SETD8, which was strongly associated with lipid storage, advanced tumor grade and stage, and poor prognosis [24]. Conversely, the increased level of the oncometabolite 2-hydroxyglutarate has been associated with epigenetic modifications which promote a neoplastic phenotype [25].

Many authors analyzed genetic and pathological features and revealed that aberrant metabolism is recurrent in ccRCC cells. These findings led to widespread metabolic profiling studies, intending to define a relationship with cancer behavior in terms of aggressiveness, prognosis, and therapeutic responsiveness [26–31].

Moreover, recent studies have also revealed a crucial role of noncoding RNAs (ncRNAs) in the regulation of different processes of neoplastic cells. Specifically, long noncoding RNAs (lncRNAs), which are large RNA transcripts more than 200 nucleotides in length, are aberrantly expressed in many human cancers, control cellular energy metabolism, and have integrative functions in cancer cells' pathogenesis and development. In recent years, the integration of their role in ccRCC metabolism revealed their potential in biomarker detection and therapeutic-targeting research. However, further research is still required to fully understand the numerous unanswered questions on the biological functions of lncRNAs [32]. In a previous article [33], we reviewed the different ccRCC-altered pathways based on an in-depth analysis of the available data on the ccRCC metabolome.

In this review article, we provide an update on the current state-of-the-art in ccRCC metabolome research, integrating information acquired from lncRNAs studies and evaluating the possibility of uncovering novel therapeutic targets.

2. Metabolic Pathway Understanding: Where Do We Stand?

2.1. Lactate Metabolism

The Warburg effect was been one of the earliest sources of evidence of metabolic reprogramming for ccRCC. Even in the presence of abundant oxygen availability, most cancer cells produce energy predominantly by glycolysis, whereas most normal cells produce energy by mitochondrial oxidative phosphorylation. This tumor-specific Warburg effect provides the energy and biosynthetic substrates needed to promote tumor progression [34].

The Warburg effect involves the modification of metabolic enzymes, such as hexokinase 2 (HK2), pyruvate kinase type M2 (PKM2), glucose transporter 1 (GLUT1), lactate dehydrogenase (LDH), and lactate transporters (monocarboxylate transporters (MCTs)) [35–37], as well as the activation of numerous transcription factors, including c-Myc, NF- κ B, and hypoxia-inducible factor 1 α (HIF-1 α) [34,36–40]. In ccRCC, VHL/HIF activity significantly alters cell glucose input and utilization [41–43]. The inactivation of VHL in ccRCC leads to the aberrant accumulation of the transcription factors hypoxia-inducible factor (HIF)-1 α and HIF-2 α , despite normoxia with the resultant upregulation of pathways involved in glycolysis, fatty acid (FA), and glycogen synthesis [41–43] promoting a lactate-rich environment [34,44,45] (Table 1).

Table 1. Summary of main altered metabolites and pathways in RCC.

Pathway	Metabolite	Sample	Variation in RCC	Reference
Glycolysis	Maltose	Tissue	↑	[46]
	Maltotriose	Tissue	↑	[46]
	Maltotetraose	Tissue	↑	[46]
	Maltopentaose	Tissue	↑	[46]
	Maltohexaose	Tissue	↑	[46]
	Fructose-6-phosphate	Tissue	↑	[46]
	Fructose-1,6-phosphate	Tissue	↑	[46]
	3-phosphoglycerate	Tissue	↓	[46]
	2-phosphoglycerate	Tissue	↓	[46]
	Phosphoenolpyruvate	Tissue	↓	[46]
	Lactate	Tissue	↑	[46–48]
		Urine	↑	[7]
	Pyruvate	Tissue	↑	[46–48]
	Urine	↑	[7]	
TCA cycle	Malate	Tissue	↓	[47]
	Fumarate	Tissue	↓	[48]
	Citrate	Urine	↓	[7]
	L-2-hydroxyglutarate	Tissue	↑	[25]
Pentose Phosphate Pathway	Arabitol	Tissue	↓	[46]
	Xylitol	Tissue	↓	[46]
	Xylonate	Tissue	↓	[46]
	Glucose-6-phosphate	Tissue	↑	[46]
	Ribose-5-phosphate	Tissue	↑	[46]
	Ribulose-5-phosphate/xylulose 5-phosphate	Tissue	↑	[46]
	Sedoheptulose-7-phosphate	Tissue	↑	[46]
Biosynthesis of unsaturated FA	Arachidonate (20:4n6)	Tissue	↓	[49,50]
	Arachidate (20:0)	Tissue	↑	[49]
	Cis-vaccenate (18:1n7)	Tissue	↑	[49,50]
	Dihomo-linoleate (20:2n6)	Tissue	=/↑	[49,50]
	Dihomo-linolenate (20:3n3 or n6)	Tissue	↑	[49,50]
	Docosadienoate (22:2n6)	Tissue	↑	[49]
	Docosahexaenoate (22:6)	Tissue	↓	[49,50]
	Docosapentaenoate (22:5)	Tissue	=/↓	[49,50]
	Eicosapentaenoate (20:5n3)	Tissue	↓	[49,50]
	Eicosenoate (20:1n9 or 11)	Tissue	↑	[49]
	Erucate (22:1n9)	Tissue	↑	[49]
	Linoleate (18:2n6)	Tissue	↑	[49,50]
	Linolenate (18:3n3 or 6)	Tissue	↑	[49]
	Nervonate (24:1n9)	Tissue	↑	[49]
	Oleate (18:1n9)	Tissue	↑	[49]
	Palmitate (16:0)	Tissue	↑	[49,50]
	Palmitoleate (16:1n7)	Tissue	↑	[49,50]
Stearate (18:0)	Tissue	↑	[49]	
FA elongation	Palmitate (16:0)	Tissue	↑	[49]
Arachidonic acid metabolism	Arachidonate (20:4n6)	Tissue	↓	[44,49]
	5-HETE	Tissue	↓	[44,49]

	5-oxo-HETE	Tissue	↓	[44,49]
	PGE2	Tissue	↓	[44,49]
	Squalene	Tissue	↓	[44,49]
	7-alpha-hydroxycholesterol	Tissue	↓	[44,49]
	Desmosterol	Tissue	↓	[44,49]
Cholesterol biosynthesis	Cholesterol	Tissue	↓	[44,49]
	Cholesterol ester	Tissue	↑	[44,49]
	7-Dehydrocholesterol	Tissue	↓	[44,49]
	7-HOCA	Tissue	↓	[44,49]
	7-beta-hydroxycholesterol	Tissue	↓	[44,49]
	Tryptophan	Tissue Serum	↓	[45,50]
	Kynurenine	Tissue Serum	↓	[45,50]
	N-formylkynurenine	Urine	↑	[46,51]
Tryptophan metabolism	3-hydroxy-Lkynurenine	Urine	↑	[46,51]
	5-hydroxy-L-tryptophan	Urine	↑	[46,51]
	Serotonin	Urine	↑	[46,51]
	Acetyl-N-formyl-5-methoxy-kynurenamine	Urine	↓	[46,51]

Arrow indicates accumulation (↑) or deprivation (↓). (=) indicates no variation.

Lactate, once considered a byproduct of anaerobic glycolysis, plays a crucial role in tumor formation, maintenance, and treatment response [45–53]. Several investigations have linked lactate generation to tumor growth and resistance to therapy, angiogenesis, metastasis, immunological evasion, and radio-resistance [54,55]. There is also growing evidence linking the overexpression of lactate dehydrogenase A (LDHA) to the growth of tumor cells.

Zhao et al. [56] determined through in vitro and in vivo investigations that LDHA improves RCC tissues and accelerates tumor migration and invasion via the epithelial–mesenchymal transition (EMT). In addition, a high level of LDHA may act as a predictor of poor outcomes in individuals with RCC [57].

Recently, Sun et al. [58] investigated the global influence of lactate-related genes (LRGs) on prognostic significance, tumor microenvironment characteristics, and therapeutic response. They analyzed data from The Cancer Genome Atlas (TCGA), E-MTAB-1980, and GSE22541 cohorts and identified 17 differentially expressed LRGs, 3 of which were determined to construct a lactate-related prognostic signature (LRPS) using LASSO and Cox regression analyses. This signature could classify patients with RCC into low- and high-risk groups, and showed a robust survival prediction efficiency.

The signature included three genes (HADH, FBP1, and TYMP) with a fundamental role in the development of different malignancies.

The short-chain L-3-hydroxy acyl-CoA dehydrogenase (HADH) gene, which encodes the HADH enzyme, is involved in the third step of FA β -oxidation [59]. Its overexpression seems to be related to poor clinical outcomes, cell migration, and invasion in acute myeloid leukemia, colon cancer [60,61], and gastric cancer [62]. A reduced expression of HADH was associated with immune infiltration and a poor prognosis in RCC patients [63].

Fructose-1,6-bisphosphatase 1 (FBP1) is a gluconeogenic rate-limiting enzyme that could regulate the uptake of glucose and the secretion of lactate by alleviating the level of glycolysis and NADPH in RCC cells under the influence of HIFs.

Thymidine phosphorylase (TYMP), a platelet-derived endothelial cell growth factor, is overexpressed in tumor cells and surrounding extra matrix cells. It catalyzes the reversible phosphorolysis of thymidine [64] and is upregulated in multiple solid tumors

[65]. This protein was associated with the expression of a number of immunocyte markers and may have a function in controlling the immunological response, indicating its potential relevance as an immunotherapy target [64,66].

Furthermore, LRPS-based risk groups showed different immune components with significant differences in prognosis and immune cell infiltration. Moreover, the tumor metabolic symbiosis hypothesis [67], which asserts that lactate may be employed as an energy source in the tumor microenvironment [34], has been put forth. Miranda-Gonçalves et al. [68] showed that increased extracellular lactate, exported by MCTs, decreases sirtuin-1 (SIRT1) expression and activity. SIRT1 is an NAD⁺-dependent class III histone deacetylase involved in RCC epigenetic mechanisms. In their findings, decreased SIRT1 activity resulted in increasing global H3 and H3K9 acetylation.

Due to SIRT1 inhibition, lactate showed a reversible influence on histone deacetylation levels and caused histone hyperacetylation in vitro and in vivo. Previous studies showed that histone acetylation was involved in the transcriptional regulation of EMT-related genes and associated pathways [69–71]; furthermore, other results suggest that SIRT1 suppresses the EMT and metastasis process by deacetylating SMAD4 [72,73].

SMAD proteins are a family of intracellular mediators that control TGF-superfamily signaling, and SMAD4 is one of its members. It functions as a convergent node in the SMAD pathways that are located downstream of the TGF- β RI and TGF- β RII receptors. In order to bind particular DNA sequence motifs and modify the expression of target genes, it can interact with all R-SMAD proteins [74,75].

According to Lichner Z et al. [76], SMAD4 plays a critical role in enhancing EMT activation and stem cell-like characteristics of RCC cell lines.

Interestingly, in Miranda-Gonçalves' study, treatment with nicotinamide (NAM), a noncompetitive SIRT1 inhibitor, paralleled lactate effects and promoted cell aggressiveness. On the other hand, alpha-cyano-4-hydroxycinnamate (CHC), a lactate transporter inhibitor, reduced cancer cell migration and attenuated the malignant phenotype. The authors explained how lactate exposure or NAM treatment decreased SIRT1 and enhanced N-cadherin and vimentin expression in RCC cell lines.

Moreover, they observed high SMAD4 acetylation levels after lactate and NAM treatment due to decreased SIRT1 activity and increased β -catenin protein levels, promoting an EMT-invasive phenotype (Figure 1).




Figure 1. In normal cells, SIRT1 suppresses EMT and metastasis process by deacetylating SMAD4. In RCC, decreased SIRT1 activity and subsequent increased β -catenin protein levels promote an

EMT-invasive phenotype. The expression levels of miR-203 in RCC cancer cells are lower than in normal cell lines. miR-203 binds to a target site and attenuates HOTAIR expression. HOTAIR enhances RCC cell migration by regulating the IGFBP2 expression. The HOTAIR-IGFBP2 axis induces glycolytic gene expression, correlating with increased proliferative and migratory capacity.

In addition, it was demonstrated that the exposure of normal kidney cell lines to lactate and a tumor cell-conditioned medium resulted in cellular changes identical to those identified in tumor cells, and hence, contributed to the pseudo-transformation of nearby normal cells and the aggressiveness of RCC. Focusing on EMT, further different approaches have been conducted to obtain new details about this shift. Dasgupta et al. [77] investigated the role of miR-203, a regulatory microRNA, in the regulation of lncRNA Hox antisense intergenic RNA (HOTAIR). According to these findings, the expression levels of miR-203 in RCC cell lines and patient tumor samples were lower than in normal cell lines and normal tissue, respectively. In contrast, HOTAIR had higher expression levels in RCC cell lines and clinical samples than their matched normal tissues or normal cell lines. They described how miR-203 binds to a target site and attenuates HOTAIR expression in renal cancer cells. They found that miR-203 overexpression in RCC cells increased the epithelial markers E-cadherin and claudin, with a concomitant decrease in the mesenchymal marker vimentin at both the mRNA and protein levels. Thus, this report envisages that miR-203 and HOTAIR may be helpful in RCC therapeutics.

Katayama H et al. [78] investigated the role of HOTAIR and demonstrated that HOTAIR enhances RCC cell migration by regulating the insulin growth factor-binding protein 2 (IGFBP2) expression. The HOTAIR-IGFBP2 axis induces glycolytic gene expression and maintains a high flow of glycolysis in ccRCC cells, which correlates with their proliferative and migratory capacity and may represent a specific therapeutic target for ccRCC.

2.2. The Leading Role of Transporters

The altered expression of glucose transporters is one of the major phenotypic characteristics of RCC. Renal cells express multiple members from the GLUT family of passive glucose transporters, e.g., GLUT1 and GLUT2 [79].

The increased GLUT1 expression in RCC cells is associated with the reduction in infiltrating CD8⁺ T cells, indicating a role of GLUT1 in the immune-escape machinery of the renal cancer cells [80]. Furthermore, this lower infiltration of CD8⁺ T cells might be caused by increased lactate formation due to enhanced lactic acid fermentation in the RCC cells, as lactate hinders T-cell activity [81].

The premise for diagnosis and staging by positron emission tomography employing (18F) fluorodeoxyglucose (18F-FDG PET) is the acceleration of glucose buildup via GLUTs in cancer cells [82,83]. However, 18F-FDG PET is unable to identify certain malignancies, including RCC, and its use for diagnosis and staging is not generally advised [83,84]. Recent investigations have suggested that sodium-glucose transporters (SGLTs), an additional class of glucose transporters not detectable by 18F-FDG PET, may contribute to glucose consumption in these malignancies. SGLT-1 and SGLT-2 are expressed in multiple cancer types (including RCC) and might even be involved in glucose transport in tumor tissue [85–91].

Recently, Kobayashi et al. [83] examined SGLT expression via immunohistochemistry in RCC tissues and suggested that elevated SGLT-2 expressions could be related to unfavorable outcomes.

An immunohistochemical analysis of 68 RCC tissue specimens showed that increased SGLT2 expression was significantly associated with shorter overall survival (OS) ($p < 0.01$), regardless of metastatic status.

Genes encoding lactate transporters, e.g., MCT1 and MCT4, are often upregulated in aggressive renal tumors [92,93].

Kim et al. provided a simultaneous analysis of MCT1 and MCT4 in ccRCC and demonstrated that overexpression predicted progression-free survival [92]. A recent study confirmed these results for MCT1 and, for the first time, directly correlated MCT1 and GLUT1 with the tumor grade, consistent with that reported previously for cervix carcinoma [94]. This central role of MCT1 and GLUT1 also concerns prognosis, with the mRNA level of both correlated with OS.

In 2021, using a public database, Yoo et al. [95] evaluated the link between the expression level of MCT members in renal cell cancers and the survival rate of patients.

MCT9 was found to be widely and selectively expressed in human kidney cells, but its expression was drastically reduced in renal malignancies. Moreover, its overexpression inhibited the growth of RCC cells. MCT9 was identified as a transporter for carnitine rather than urate [96]. Since the majority of free carnitine is totally reabsorbed by the kidney, it is possible that MCT9, the most common MCT member, contributes to carnitine transport in normal renal cells. Hence, a significant decrease in MCT9 expression in renal tumors may completely abrogate its function, which may be associated with dysregulated energy balance and muscle loss during tumor progression.

2.3. The Oncogenic Role of G6PD

G6PD dysregulation has been reported in RCC and various types of human cancers, and elevated levels of G6PD in association with higher levels of PPP-derived metabolites suggests a prominent role of this pathway in RCC-associated metabolic alterations [46,97,98].

Many authors showed that a high expression of G6PD in ccRCC predicted poor outcomes for ccRCC patients, identifying the oncogenic role of G6PD in RCC.

Through in vitro and in vivo analysis, Zhang et al. [99] investigated the impact of ROS accumulation on the NF- κ B signaling pathway, pSTAT3, and G6PD in ccRCC.

They triggered or inhibited ROS production in RCC cell lines and observed that the G6PD mRNA expression level was increased or decreased, respectively. These results were consistent with a previous study using different ccRCC cell lines, which reported that ROS, cytokines, and other stresses could stimulate the continuous activation of pSTAT3, NF- κ B, and MAPK signals [99–104] and promote the occurrence and development of RCC [100,105,106].

It was shown that pSTAT3 and NF- κ B might regulate a range of tumorigenesis-related genes either synergistically or independently [107]. Overactivation of NF- κ B signaling has been shown to promote RCC oncogenic transformation [108]. High pSTAT3 expression is anticipated to be an independent prognostic molecule for individuals with ccRCC [109,110]. In numerous physiological and pathological processes, such as B-cell activity [111], cancer cell nutrition [107,112], and mitochondrial fusion [113], NF- κ B and STAT3 signaling pathways were found to interact. In addition, G6PD might accelerate the growth of ccRCC by enhancing ROS generation and pSTAT3 signaling activity, and pSTAT3 demonstrated a positive feedback control of G6PD transcription [100].

Therefore, Zhang et al. demonstrated that significantly reduced or increased activities of the NF- κ B signaling pathway were found in ccRCC cells following treatment with an ROS scavenger or stimulator, respectively, which was consistent with the changes in pSTAT3 signaling activity and G6PD expression. According to the results presented above, NF- κ B signaling and pSTAT3 were transcriptional regulators that may have a cooperative effect on G6PD overexpression in ccRCC. Following a thorough analysis, it was determined that ROS caused an overactivation of NF- κ B and pSTAT3 signaling. These two signaling pathways activated each other and formed a transcriptional complex including pSTAT3 and p65, instead of p50. The p65/pSTAT3 complex occupied the pSTAT3-binding site on the G6PD transcription promoter and synergistically facilitated G6PD overexpression, contributing to ccRCC proliferation.

Different mechanisms were discovered by the same authors who recently described, through their *in vitro* experiments on RCC cell lines, the regulatory effect of SIRT2 on G6PD in RCC [114].

Firstly, they observed, according to previous studies, that SIRT2 was highly expressed and played an oncogenic role in ccRCC.

Then, through the coimmunoprecipitation (Co-IP) assay, they observed that SIRT2 enhanced glucose 6-phosphate dehydrogenase (G6PD) activity by deacetylation. Furthermore, western blot assays with glutaraldehyde crosslinking showed that G6PD active dimer formation was significantly increased with SIRT2 overexpression, whereas G6PD monomer formation showed opposite results.

In addition, they observed that SIRT2 overexpression favored G6PD protein stability in ccRCC by reducing G6PD ubiquitination and enhancing small ubiquitin-related modifier 1 (SUMO1). In their experiments, G6PD activity and G6PD dimer formation decreased significantly after treatment with SUMOylation inhibitor 2-D08.

In recent studies, Zhang et al. [114–116] also illustrated the association between G6PD activity and RCC progression, proliferation, and the migration rate, focusing on MMP2 and MMP9 activity and expression.

Due to their ability to degrade the essential elements of basement membranes, MMP2 and MMP9, also known as gelatinase A and gelatinase B, are thought to be the significant MMPs involved in the invasion and metastasis of several cancers. They discovered a positive correlation between G6PD and MMP2 by using a reverse transcription-quantitative PCR, Western blotting, enzyme activity assay, and immunohistochemistry analysis in cell and murine models, and in human specimens[116].

However, in 2021 [117], they observed no significant difference in MMP2 expression in the analysis of large numbers of ccRCC clinical samples and normal kidney tissue, and no RCC prognosis association [118], indicating that G6PD-mediated ccRCC progression may be dependent on other more critical underlying mechanisms. Subsequently, they studied the correlation between the expression patterns of G6PD, Cyclin E1, and MMP9 in ccRCC to identify relationships between clinicopathological characteristics of ccRCC and the genes of interest in the prognosis of ccRCC patients.

G6PD, Cyclin E1, and MMP9 were found to be overexpressed in ccRCC and to have a positive correlation, according to a variety of *in vitro* cytological function studies and xenografted murine models. Additionally, they were associated with patients with ccRCC having a bad prognosis. Additionally, G6PD altered the dynamics of the cell cycle, aided cell proliferation and migration *in vitro*, and improved the formation of ccRCC *in vivo*, most likely by promoting Cyclin E1 and MMP9 expression.

These findings revealed the feasibility of G6PD, Cyclin E1, and MMP9 being novel biomarkers and paved the way for developing novel therapeutics for ccRCC.

ROS accumulation in RCC activates the NF- κ B signaling pathway, pSTAT3, and G6PD, which regulate tumorigenesis-related genes and promote RCC oncogenic transformation. These two signaling pathways activated each other and formed a transcriptional complex that includes pSTAT3 and p65. The p65/pSTAT3 complex occupies the pSTAT3-binding site on the G6PD transcription promoter and synergistically facilitates G6PD overexpression.

SIRT2 is highly expressed in RCC and enhances G6PD activity and stability balance through deacetylation, dimer formation, and SUMOylation (Figure 2).




Figure 2. High levels of G6PD suggest that this pathway plays a major role in metabolic changes caused by RCC.

2.4. The Metabolic Background of Lipid Droplets

Solid tumor cells require extracellular FA as a nutrient source, especially under metabolic stress conditions [119], and the dysregulation of lipid metabolism is among the most prominent changes in ccRCC.

A hallmark of ccRCC is the accumulation of cholesterol, cholesterol esters, and other lipids collected in intracellular lipid droplets (LDs) [49,120]. These dynamic organelles are responsible for lipid uptake and storage, homeostasis support, energy production, and membrane biogenesis during rapid tumor cell growth and transformation [121–124]. Furthermore, a decrease in the expression of specific FA β -oxidation enzymes has also been correlated with an increase in tumor stage, size, and grade, with a concomitant decrease in survival [125,126].

Recent studies tried to explain the metabolic and genetic background of lipid storage and droplet formation, known as a grade-dependent phenomenon [127].

When cells are under stress, LDs play a crucial role in maintaining energy and redox balance, controlling autophagy, preserving ER homeostasis, and defending cells against lipotoxicity [121]. By buffering cellular lipid saturation through the interchange of TG-resident unsaturated FA in ccRCC, LDs reduce the buildup of toxic, saturated lipids under hypoxia conditions [122].

Recently, it has been shown that two LD-associated proteins, lipid droplet protein perilipin 2 (PLIN2) and hypoxia-inducible lipid droplet-associated (HILPDA), are overexpressed in ccRCC, where they regulate lipid storage and enrich lipids that contain polyunsaturated fatty-acyl side chains [128,129]. The phospholipid-binding protein annexin A3 (AnxA3) has been described as a negative regulator of adipocyte differentiation and is downregulated in RCC. It reveals a differential expression pattern

for two isoforms of 36 and 33 kDa. Bombelli et al. [129] investigated the involvement of AnxA3 isoforms in the lipid storage modulation of ccRCC cells. They found that the increased accumulation of lipids in ccRCC cells correlated with a decrease in the 36/33 isoform ratio, and 36-kDa AnxA3 silencing in ccRCC cells increased lipid storage induced by an adipogenic medium. The subcellular distribution of AnxA3 in the cellular endocytic compartment suggested that it may negatively modulate lipid storage in ccRCC cells by interfering with the caveolin-1-dependent vesicular trafficking involved in lipid uptake and accumulation in ccRCC.

Cholesterol plays an essential role in controlling membrane fluidity and assembly and the function of lipid rafts, which contain multiple signaling cascades such as RAS, AKT, and SRC that are involved in cancer development [130,131].

Cholesterol arrives in cells through direct uptake from the diet and can be acquired through the receptor-mediated uptake of plasma lipoproteins. The low-density lipoprotein receptor (LDL-R), very low-density lipoprotein receptor (VLDL-R), and scavenger receptor B1 (SR-B1) are the major receptors involved in exogenous cholesterol uptake [132,133]. Once a lipoprotein binds to its receptor, it forms an endosome within the membrane, which translocates into cells. Following internalization and transport into the lysosome, the cholesterol ester is hydrolyzed by lysosomal acid lipase (LAL) to release the free cholesterol [134].

In ccRCC tissues, VLDL-R and LAL are upregulated and associated with lower patient survival [50,135,136].

Cells can also synthesize *de novo* cholesterol through the mevalonate pathway. This pathway starts with the condensation of acetyl-coenzyme A (CoA) and aceto-acetyl-CoA, generating 3-hydroxy-3-methylglutaryl (HMG)-CoA. The conversion of HMG-CoA to mevalonate by HMG-CoA reductase is the rate-limiting step in cholesterol biosynthesis. HMG-CoA reductase inhibitor medications, known as statins, inhibit the production of mevalonate, which is the precursor of cholesterol [137,138]. In addition, many studies have investigated their ability to inhibit the active form of oncoproteins, such as Rho and Ras pathways involved in the proliferation, migration, invasion, and survival of cancer cells [139,140].

The TCGA-KIRC project dataset revealed that HMG-CoA reductase gene expression is significantly lower in primary ccRCC compared to normal tissue [141]. Furthermore, a histologic examination of RCC primary specimens showed decreased levels of HMG-CoA reductase [142–144]. Therefore, cholesterol accumulation in ccRCC is likely the result of increased uptake rather than excessive biosynthesis from acetate.

To protect cells from the toxic effects of high free-cholesterol levels resulting from LAL hydrolysis, ACAT re-esterifies free cholesterol with FAs for storage inside the cell. High levels of CE in RCC tumors result from the increased activity of this enzyme [144].

In physiological conditions, as a consequence of insufficient intracellular lipid levels or following the stimulation of some growth factors, we observed the activation, via mammalian target of rapamycin (mTOR) signaling, of the sterol regulatory element-binding proteins (SREBPs) [142,144]. SREBPs are transcription factors that regulate enzymes involved in cholesterol and FA biosynthesis. Their activation requires proteolytic cleavage in the Golgi and translocation into the nucleus. Once inside the nucleus, they bind to the promoter regions of SREBP target genes and initiate the expression of enzymes involved in FA, TG, and cholesterol synthesis and uptake [145]. Additionally, it has been demonstrated that mTORC1 increases mitochondrial ATP generation and controls the translation of nucleus mitochondrial genes [146]. For instance, Liu et al. discovered that the LncRNA TP73-AS1 mediates the mTOR signal, encodes the nuclear mitochondrial protein SREBP1, produces ATP to enhance ccRCC cell proliferation, and suppresses apoptosis [32,144–146].

Recent research by Li et al. [147] provided an overview of the epigenetic control over SREBP signaling. They looked into the function of SETD8, a lysine methyltransferase (KMT) involved in the regulation of lysine residues in histones [148], which is implicated

in a number of biological processes, including cell cycle progression [149], transcription activation [150], and DNA damage response [151].

According to their research, SETD8 significantly affected lipogenesis by methylating the 20th lysine of histone-4, which regulated the transcription of SREBP1 as a direct target. They discovered that SETD8 depletion stopped the development of kidney tumors *in vivo*, which was based on their observations of its impact on the growth of the mice xenograft model. Furthermore, RCC cells' *in vitro* growth and metastasis were inhibited by the inhibitor UNC0379 and the siRNA downregulation of SETD8. Moreover, they demonstrated that USP17, an immediate early gene associated with a subfamily of cytokine-inducible deubiquitinating proteins (DUBs), was responsible for post-translational stabilization of the SETD8 protein by deubiquitination of the SETD8 protein [152]. Furthermore, by deubiquitinating Cdc25, which is connected to proliferation, as well as Snail and Twist, which are closely tied to metastasis, USP17, also known as DUB3, participates in the malignant transformation of cancer. Numerous studies have shown that USP17 is crucial for the development of many malignancies [147,153–159].

In 2022, Yang et al. [160] investigated the long-chain FA transferase CPT1A in ccRCC. CPT1A is decreased in ccRCC clinical samples and cell lines compared to normal samples. HIFs block CPT1A expression, reduce FA transport into mitochondria, and reroute FA to LDs for storage [161]. The authors utilized lentivirus overexpressing CPT1A to explore the neoplastic phenotypes of ccRCC, and the results showed that both tumor growth and lipid accumulation were suppressed *in vitro* and *in vivo*.

Due to enhanced cholesterol absorption and intracellular lipid accumulation caused by the expression of two class B scavenger receptors, CD36 and SRB1, in ccRCC cells, CPT1A deficiency promoted PI3K/Akt signaling activity and accelerated ccRCC cell growth. CD36 and SRB1 are members of the class B scavenger receptors [162]. CD36, counter-regulated by PPAR α [163], is upregulated in ccRCC and promotes lipid uptake. SRB1 is a transmembrane protein well-characterized as a unique multifunctional receptor for cholesterol influx and efflux that mediates cholesterol movement into and out of cells [164].

PPAR α is a crucial transcription factor that regulates the expression of proteins involved in FA uptake and β -oxidation [165]. PGC1 α is a transcriptional coactivator within the metabolic reprogramming family [166]. PPAR α and PGC1 α stimulate the transcription of the CPT1A gene [167]. Yang et al. observed that CPT1A overexpression in cell lines enhanced the expression of PPAR α and PGC1 α .

In experiments with CPT1A-overexpressing cells, there were reduced levels of CD36, ABCG1, and SRB1 proteins and suppression of the activity of PI3K/Akt signaling with decreased intracellular lipid accumulation and cell apoptosis. Mechanistically, CPT1A overexpression downregulated CD36 and SRB1 and upregulated the expression of PPAR α .

FAs, the primary components of lipids, have been found to function as substrates for energy storage, membrane formation, and signaling molecule creation. In the *de novo* synthesis of long-chain fatty acids (LCFAs), elongation and desaturation are the key stages. FA function and metabolic destiny are determined by the unsaturation degree and length. *De novo* lipogenesis yields palmitate as its primary product. It can be elongated and desaturated by SCD1 and ELOVLs to produce additional SFAs, MUFAs, and PUFAs such as oleate, palmitoleate, and stearate. These FAs, in turn, can be used to synthesize more complex lipids [49,120].

Zhang et al. [168] described how ccRCC cell lines under hypoxia upregulated SCD1 and that HIF-2 α and SCD1 had synergistic effects in sustaining cancer cell survival and migration. These results were the consequence of a positive feedback loop between HIF-2 and SCD1, mediated by the activation of the PI3K/Akt pathway. Moreover, a recent study observed that SCD1 activity reduced cell viability and sensitized cancer cells to cisplatin-induced apoptotic death [49].

Tanaka et al. [169] investigated the involvement of elongases in RCC. Previous findings revealed an increased expression of ELOVL2 and ELOVL5 in ccRCC [115] and an *ELOVL2* role in promoting LD accumulation in cell lines [170]. They explored the correlation between ELOVL2 and ccRCC progression.

They showed that ELOVL2 ablation might suppress the production of docosahexaenoic acid (DHA) and LDs in renal cancer cells, suggesting that ELOVL2 overexpression may promote LD production through endogenous DHA production in RCC. Furthermore, ELOVL may promote endoplasmic reticulum (ER) stress and CHOP upregulation, downregulating BCL-2 and MCL-1. These findings suggested that ELOVL2 may protect cells against lipotoxicity-driven apoptosis by maintaining ER homeostasis to promote tumor growth and progression in RCC (Figure 3).




Figure 3. A hallmark of ccRCC is the accumulation of cholesterol, cholesterol esters, and other lipids collected in intracellular lipid droplets (LDs). LD-associated proteins, PLIN2 and HILPDA, are overexpressed in ccRCC, regulate lipid storage, and enrich lipids that contain polyunsaturated fatty-acyl side chains. Cholesterol arrives in RCC cells through direct uptake from the diet and can be acquired through receptors: very low-density lipoprotein receptor (VLDL-R) and scavenger

receptor B1 (SR-B1). Once lipoprotein binds to its receptor, it forms an endosome within the membrane, which translocates into cells. Following internalization and transport into the lysosome, the cholesterol ester is hydrolyzed by lysosomal acid lipase (LAL) and upregulated in ccRCC to release the free cholesterol. To protect cells from the toxic effects of high free-cholesterol levels resulting from LAL hydrolysis, ACAT re-esterifies free cholesterol with FAs for storage inside the cell. High levels of CE in RCC tumors result from increased activity of this enzyme. Cholesterol de novo synthesis in ccRCC is reduced because of decreased levels of HMG-CoA reductase. Therefore, cholesterol accumulation in ccRCC is likely the result of increased uptake rather than excessive biosynthesis from acetate. SREBPs are transcription factors that regulate enzymes involved in cholesterol and fatty acid biosynthesis. Once inside the nucleus, they bind to the promoter regions of SREBP target genes and initiate the expression of enzymes involved in FA, TG, and cholesterol synthesis and uptake. SETD8 is stabilized by deubiquitination mediated by ubiquitin-specific protease 17 (USP17) and modulates the transcription of SREBP1 as a direct target by methylating the 20th lysine of histone-4 with enormous effects on lipogenesis. The long-chain fatty acid transferase CPT1A is decreased in ccRCC clinical samples and cell lines compared to normal samples. HIFs are responsible for inhibiting CPT1A expression, reducing FA transport into mitochondria, and rerouting FA to LDs for storage. CPT1A deficiency promotes the expression of two members of class B scavenger receptors, CD36 and SRB1, leading to increased cholesterol absorption and intracellular lipid accumulation. CD36 and SRB1 are members of class B scavenger receptors, which promote lipid and cholesterol uptake. Elongation and desaturation are the main steps of the de novo synthesis of long-chain FAs (LC-FAs). The length and degree of unsaturation are determinants of FA function and metabolic fate. Palmitate (16:0) is the main product of de novo lipogenesis. It can be elongated and desaturated through the activity of SCD1 and ELOVLs to generate additional SFAs, MUFAs, and PUFAs. ccRCC cell lines upregulate SCD1 and HIF-2 α , and SCD1 had synergistic effects in sustaining cancer cell survival and migration. These effects were due to a positive feedback loop between HIF-2 α and SCD1, mediated by PI3K/Akt pathway activation.

2.5. Arginine and miR-34a-5p/ASS1 Axis

The metabolism of cancer cells helps them adapt their pathological needs to fuel their accelerated proliferation and resistance to apoptosis. Arginine plays critical roles in many metabolic pathways, such as in the production of urea, nitric oxide (NO), and proline [171].

Ammonia from protein synthesis is transformed into urea by the hepatic urea cycle, which is a crucial detoxifying system [172]. The conventional cycle, on the other hand, functions as a “urea shunt” in the kidney. Large amounts of urea are normally excreted by the kidneys, which also create arginine that is exported to other organs. Tumors with altered expression of urea cycle enzymes, such as argininosuccinate synthase 1 (ASS1), argininosuccinate lyase (ASL), and arginase 2 (ARG2), produce less nitrogen waste while diverting both carbon and nitrogen to the production of anabolic biomass [172–176].

Many malignancies have been shown to have a decrease in ASS1 expression, which favors cell proliferation by allowing the CAD (carbamoyl-phosphate synthase 2, aspartate transcarbamylase, and dihydroorotase) complex to activate pyrimidine synthesis [173,177].

Furthermore, NO is considered a potent regulator of numerous cellular processes, including growth and angiogenesis [178].

In a recent study, Khare et al. [175] investigated the loss of urea cycle enzymes ASS1 and ASL in ccRCC patients and elucidated the contributions of ASS1 and ASL loss toward ccRCC progression.

They reported a considerable growth inhibition in ccRCC cells with the simultaneous re-expression of ASS1 and ASL.

According to their findings, ccRCC tumors and cell lines had lower levels of NO metabolites and decreased NOS expression. They proposed that the depletion of ASS1 and ASL changes the cellular NO metabolism and promotes cell proliferation by controlling the cytotoxic effects of NO production.

In addition, they demonstrated that the expression of ASS1 and ASL modulates cellular nucleotide synthesis and aspartate levels. These findings show that ASS1 and ASL

seem to be potential metabolic tumor suppressors in ccRCC, and that their loss conserves cellular aspartate pools and regulates NO production to offer ccRCC cells a proliferative advantage. ASS1- and ASL-deficient cells are arginine auxotrophs and must obtain their intracellular supply from external sources. Consequently, arginine deprivation has been considered as a promising potential treatment for malignancies lacking ASS1 and ASL [179,180].

ARG2 is persistently downregulated in ccRCC tumors relative to healthy tissue [181]. Reducing pyridoxal-5'-phosphate, an essential biosynthetic cofactor, and preventing a toxic buildup of polyamines [175,181] are two primary processes by which decreased ARG2 levels promote tumor growth. Consequently, the simultaneous downregulation of ASS1, ASL, and ARG2 contributes to the overall conservation of intracellular aspartate by preserving pyridoxal phosphate (PLP) and diverting aspartate away from the urea cycle.

Intriguingly, all three enzymes inhibit ccRCC cell growth in a catalytically dependent manner, as the re-expression of enzyme-dead mutants had no effect on the growth dynamics of ccRCC cells [175].

Further studies showed the role of competitive endogenous RNAs (ceRNAs) in the repression of ASS1 in ccRCC. Recent research by Polisenio et al. [182] demonstrates that pseudogenes can function as ceRNAs to modify other RNA transcripts in tumors by competing with miRNAs.

The microRNAs (miRNAs) are a class of noncoding RNAs that can bind to the 3' untranslated region (3'UTR) of target gene transcripts to inhibit translation or reduce the stability of messenger RNA (mRNA) [183].

ASS1 is a target of miR-34a-5p and can be negatively regulated by miR-34a-5p [184].

Wang et al. [184] discovered that the androgen receptor (AR), which plays an essential role in tumor proliferation in cancer [185–187], could regulate ASS1 expression in RCC by regulating the ceRNA activity of ASS1P3, an ASS1 pseudogene.

In their findings, AR expression was negatively correlated with ASS1 expression, thus contributing to RCC tumor progression.

The pseudogene ASS1P3 could function as a ceRNA to regulate the expression level of its corresponding gene via miR-34a-5p. A decreased level of ASS1P3 expression led to the inhibition of ASS1 by miR-34a5p and increased cell proliferation.

Thus, the increased expression of ASS1P3 could reduce cell proliferation with a potential therapeutic modality for advanced RCC.

Although the authors did not detect a correlation between AR and ASS1P3 expression, they postulated that AR undergoes a physical interaction with ASS1P3 that inhibits ASS1P3's interaction with miR-34a5p. Therefore, miR-34a5p might operate as an oncogene in this circumstance, and by reducing the expression of ASS1 and ASS1P3, it could partially reverse the AR-induced drop in ASS1 expression.

Similarly, Zeng et al. [188] recently described the involvement of lncRNA 00312 in the miR-34a-5p/ASS1 axis in RCC.

In their findings, lncRNA 00312 expression was significantly downregulated in RCC tissues. In addition, they showed that there were binding sites of miR-34a-5p in the 3' region of lncRNA 00312.

Thus, lncRNA 00312, which is mostly localized in the cytoplasm of RCC cells, might function as a ceRNA to bind to microRNAs, thereby preventing microRNAs from inhibiting target gene transcripts.

The decreased expression of lncRNA 00312 in RCC was associated with a poorer prognosis according to tumor size, pathological grade, and TNM stage in RCC patients.

By overexpressing lncRNA 00312 in RCC cells, the researchers discovered that lncRNA 00312, which induces an increase in ASS1, could reduce the proliferation, invasion, and death of RCC cells. These findings imply that lncRNA 00312 could be a viable therapeutic gene (Figure 4).




Figure 4. ASS1 can be negatively regulated by miR-34a-5p. The decrease in ASS1 expression favors cell proliferation. The pseudogene ASS1P3 could function as a ceRNA to regulate the expression level of its corresponding gene by competing with miR-34a-5p. A decreased level of ASS1P3 expression leads to the inhibition of ASS1 by miR-34a5p and increased cell proliferation. AR undergoes a physical interaction with ASS1P3 and regulates ASS1 expression in RCC by regulating the ceRNA activity of ASS1P3, contributing to RCC tumor progression. A decreased level of ASS1P3 expression leads to the inhibition of ASS1 by miR-34a5p and increased cell proliferation. IncRNA 00312 expression is significantly downregulated in RCC. Decreased expression of IncRNA 00312 in RCC is associated with a poorer prognosis.

3. Metabolomic Biomarkers in Tumor Staging and Drug Efficacy

The in-depth understanding of RCC metabolome has provided new opportunities for biomarker detection. The main field of application has been the employment of these metabolites to stratify cancer subtypes and stages, and to evaluate drug sensitivity. Monitoring tumor progression through specific biofluid metabolite profiles has become a significant translational opportunity for urological cancers [189–194].

In a cohort of 61 patients with renal tumors and 68 healthy controls, Zhang et al. [195] used LC-MS to study the urine metabolomes.

Urine metabolic profiling could help distinguish RCC from benign renal tumors and healthy controls. With an AUC of 0.868 for the ten-fold cross-validation and 0.873 for the validation group, it was observed that a metabolite panel consisting of cortisol, testosterone, and L-2-amino adipate adenylate had a high ability to discriminate RCC from benign tumors. With an AUC of 0.841 for the ten-fold cross-validation and 0.894 for the validation group, the panel of amino adipic acid, 2-(formamido)-N1-(5-phospho-d-ribose) acetamidine, and alpha-N-phenylacetyl-l-glutamine was also able to identify the RCC group from the healthy control group.

According to a pilot study by Falegan et al. [196], urine and serum metabolomics may help distinguish between benign renal tumors and RCC, as well as for staging RCC. The pathological stage was used to stratify the malignant groups. In comparison to benign

masses, they discovered RCC to have altered amounts of glycolytic and TCA cycle intermediates. For an ^1H NMR-analyzed serum, OPLS-DA plots distinguished between benign masses versus pT1 (AUC = 0.83), benign masses versus pT3 (AUC = 0.87), and benign masses versus pT3 (AUC = 0.98) for urine samples. For the GCMS-analyzed serum, separation was seen between benign masses and pT3 (AUC = 0.93), pT1 and pT3 (AUC = 0.98), and benign masses and pT3 (AUC = 0.93) for urine samples.

Using urine-based metabolomics, Bifarin et al. [197] recently determined the RCC stage. A twenty-four-metabolite panel that successfully enabled RCC staging and distinguished between early RCC and advanced RC was obtained through a combined LC-MS and NMR method.

They discovered that when early RCC and advanced RCC groups were compared to healthy control samples, the levels of apo-[3-methylcrotonoyl-CoA:carbon-dioxide ligase (ADP-forming)], dihydrouridine, acetone, pyruvate, hydroxypropyl-asparagine, 7-aminomethyl-7-carbaguanine, and lys-gly/gly-lys increased. Additionally, these metabolites resulted in an increase when advanced RCC samples were compared to early RCC samples, suggesting that these metabolites could be used to distinguish between advanced and early RCC, as well as help distinguish both RCC stages and healthy controls.

Conversely, they discovered that early RCC was associated with lower levels of N, N-dimethyl-histidine, succinic anhydride, diethyl-2-methyl-3-oxosuccinate, cytosine dimer, 3-hydroxyanthranilic acid, and choline when compared to healthy controls. However, these levels grew in advanced RCC in comparison to control samples. Additionally, glycine, citrate, and 4-guanidinobutanoic acid had lower relative abundances in advanced RCC compared to early RCC. When early RCC samples were compared to healthy controls, both metabolites had larger relative abundances than when advanced RCC samples were matched with healthy controls (Table 2).

The acquisition of drug resistance is a crucial factor in RCC pharmacologic management and is responsible for the disease's poor prognosis and limited long-term responses [198,199]. As a result, the first-line therapy for RCC includes tyrosine kinase inhibitors such as sunitinib, pazopanib, tivozanib, and cabozantinib, as well as mTOR inhibitors such as temsirolimus and everolimus [200,201]. Furthermore, thanks to the discoveries about the immunological background of RCC [202–204], a number of immune checkpoint inhibitors (ICIs) for the treatment of metastatic renal cell carcinoma (mRCC) were approved in recent years [205–208].

Recent studies [209–213] discovered the potential role of metabolic profiles in detecting biomarkers that predict drug efficacy to avoid these problems, reduce costs, and improve patient survival [214].

In 2018, Hatakeyama et al. [209] showed that intracellular levels of several metabolites involved in energy processes were found to be higher in sunitinib-resistant cell lines. Fructose 6-phosphate, D-sedoheptulose 7-phosphate, and glucose 1-phosphate levels were all significantly elevated in cells in the sunitinib-resistant condition. These findings suggest a faster rate of glycolysis and a larger absorption of glutamine into the TCA cycle. The increased expression of glutamine transporters in sunitinib-resistant cells supported this evidence. Additionally, the analysis suggests that resistant primary cells had significantly higher levels of glutathione and myo-inositol than sensitive cells, indicating that resistant cells had better antioxidant activity as a defense against sunitinib's anticancer effects.

Jobard et al. [212] looked into the pretreatment and serial on-treatment sera of 121 patients enrolled in the French clinical trial TORAVA, in which 171 randomly selected patients with mRCC were treated with either a bevacizumab and temsirolimus combination or a standard regimen of either sunitinib or interferon- α plus bevacizumab [194]. Nuclear magnetic resonance spectroscopy was used to produce metabolic profiles, which were then compared during or between treatments.

Serum profiles were differentiated between before and after several weeks of treatment using a multivariate statistical analysis. After just two weeks of medication, the combination of bevacizumab and temsirolimus began to affect the patient's metabolism more quickly than a normal treatment would. Lipids and carbohydrates were among the metabolites linked to the discrimination, which is consistent with the medicines' known side effects and RCC metabolism [215]. The faster host metabolism modification shown in the experimental arm was caused by temsirolimus, according to a comparison of the metabolic profiles for the three arms. These outcomes demonstrated that medication responses and side effects might be predicted using a pharmacometabolomic technique.

The metabolic adjustments that underlie the success and failure of immunotherapy were studied by Mock et al. [211]. Based on the influence of the T-cell metabolism and a potential prognostic value demonstrated by transcriptomic analysis, they compared the serum lipid content between responders and nonresponders between the first and third cycles. They found that very-long-chain FA-containing lipids appeared to act as sensitizers to immune treatment. Similar to this, Li et al. [213] examined serum samples obtained from various RCC patients using LC-MS (at 4 and 8 weeks of treatment). An elevated kynurenine/tryptophan ratio was found via serum metabolite profiling. Kynurenine, a byproduct of tryptophan metabolism, suppresses the immune system. A lower OS rate for RCC patients was linked to the altered kynurenine/tryptophan ratio and an adaptative resistance mechanism.

In a recent study, Yao et al. [216] used 100 previously reported metabolic (MTB) pathways to quantify the metabolic landscape of the 729 ccRCC patients. Based on metabolism-related genes, they described three molecular subtypes of RCC and, using the principal component analysis (PCA), built the MTB score to calculate the metabolic pattern of individuals. Their results investigated the immune response and metabolic variations in the TCGA RCC cohort. They described how in individuals with ICI-resistance-associated pathways, the cluster with an unfavored prognosis demonstrated a high score of hypoxia and Wnt/beta-catenin signaling. These findings were consistent with previous studies which described HIF-related hypoxia and Wnt/beta-catenin signaling as pro-tumorigenic activities [217,218]. In this cluster, they described the highest immune and stromal scores, which may contribute to its poor outcomes. The cluster with better OS manifested a declined score of hypoxia and Wnt/beta-catenin signaling, which may be more likely to benefit from ICI therapy.

Variations in MTB scores were associated with cancer heterogeneity, treatment regimen, and clinical outcomes.

Patients who responded to ICI therapy and anti-VEGF medication had significantly higher MTB scores, demonstrating the prognostic value of this test. Overall, the data imply that patients with high MTB scores might benefit from ICI therapy and anti-VEGF medications [216], suggesting their potential role in therapy management.

Table 2. Summary of potential biomarkers in RCC staging and drug efficacy evaluation.

	Metabolite	Sample	Variation	Ref.	
Diagnosis/Staging			RCC vs. benign tumors		
	Cortisol	Urine	↑	[195]	
	Testosterone	Urine	↑		
	L-2-aminoadipate adenylate	Urine	↑		
				RCC vs. healthy controls	
	Aminoadipic acid	Urine	↑		
	2-(formamido)-N1-(5-phospho-d-riboseyl) acetamidine	Urine	↑		
	Alpha-N-phenylacetyl-l-glutamine	Urine	↑		
				RCC vs. benign	[196]
Citrate	Serum	↓			

	Urine	↓	
Methanol	Serum	↓	
Threonine Glycine	Serum	↓	
Histidine Taurine	Serum	↓	
Glutamine	Serum	↓	
5-methylcytosine	Serum	↓	
Eicosanoate	Serum	↓	
Succinate	Urine	↓	
Glycine	Urine	↓	
3-hydroxybutyrate creatinine	Urine	↓	
2-aminoisobutyrate	Urine	↓	
Phenylalanine	Urine	↓	
Methylhistidine	Urine	↓	
Acetate threonine	Urine	↓	
Gluconate	Urine	↓	
Thymine	Urine	↓	
Mannitol	Urine	↓	
2-oxoisocaproate	Serum	↑	
Creatine	Serum	↑	
Isoleucine	Serum	↑	
Glutamate	Serum	↑	
Ornithine	Serum	↑	
Tyrosine	Serum	↑	
Octadecanoate	Serum	↑	
Galactose	Serum	↑	
Pyruvate	Serum	↑	
	Urine	↑	
Lactate	Serum	↑	
	Urine	↑	
Oxypurinol	Urine	↑	
Gluconate	Urine	↑	
Hypoxanthine	Urine	↑	
Malonate	Urine	↑	
Betaine	Urine	↑	
Tryptophan	Urine	↑	
Trigonelline	Urine	↑	
Dimethylamine	Urine	↑	
Glucose	Urine	↑	
Erythritol	Urine	↑	
2-oxoglutarate	Urine	↑	
Myo-inositol	Urine	↑	
Apo-[3-mthylcrotonoyl-CoA:carbon-dioxide ligase]	Urine	↑	Early/Advanced RCC vs. healthy controls [197]
Dihydrouridine	Urine	↑	
Acetone	Urine	↑	
Pyruvate	Urine	↑	
Hydroxypropyl-asparagine	Urine	↑	
7-aminomethyl-7-carbaguanine	Urine	↑	
Lys-gly/gly-lys	Urine	↑	

	Apo-[3-methylcrotonoyl-CoA:carbon-dioxide ligase]	Urine	Advanced vs. early RCC	↓	
	Dihydrouridine	Urine		↑	
	Acetone				
	Pyruvate	Urine		↑	
	Hydroxypropyl-asparagine	Urine		↑	
	7-aminomethyl-7-carbaguanine	Urine		↑	
	Lys-gly/gly-lys	Urine		↑	
	N,N-dimethyl-histidine	Urine	Early RCC vs. healthy controls	↓	
	Succinic anhydride	Urine		↓	
	Diethyl-2-methyl-3-oxosuccinate	Urine		↓	
	Cytosine dimer	Urine		↓	
	3-hydroxyanthranilic acid	Urine		↓	
	N,N-dimethyl-histidine	Urine	Advanced RCC vs. healthy controls	↑	
	Succinic anhydride	Urine		↑	
	Diethyl-2-methyl-3-oxosuccinate	Urine		↑	
	Cytosine dimer	Urine		↑	
	3-hydroxyanthranilic acid	Urine		↑	
Drug Efficacy	Fructose-6-phosphate	Sunitinib		↓	[209]
	D-sedoheptulose 7-phosphate	Resistant		↓	
	Glucose 1-phosphate	Cell lines		↓	
	Lipid species	Serum	Bevacizumab+temsirolimus vs. sunitinib+interferon-alfa + bevacizumab	↑	
	Lipoproteins	Serum		↑	[212]
	Very-long-chain FA	Serum	Responders vs. nonresponders to immunotherapy	↑	[211]
	Kynurenine/tryptophan	Serum		↑	[213]

Arrow indicates accumulation (↑) or deprivation (↓).

4. Future Perspectives

The metabolomic approach used to study ccRCC biology has led to an increase in the knowledge of the pathological background of this disease. In addition, the integration with other omics branches has allowed for a more profound identification of a typical stage-related metabolic fingerprint.

In the last decade, metabolomics studies on the Warburg effect and lipidic metabolism described the main pathways potentially involved in the ccRCC signature.

Moreover, the discovery of lncRNAs implemented the knowledge of pathways. lncRNAs act as regulators, which can directly or indirectly exert a broad and complex influence on ccRCC metabolic pathways and products.

The integration of their role provided a basis for further research on tumor metabolism, the identification of new tumor markers, and potential therapeutic targets in the future.

In addition, a correct interpretation of the genetic landscape identified by these multiomics studies, even using artificial intelligence techniques, should help establish a better characterization of the pathways involved [219].

However, the results and experts' interpretations of this complex network appear to be fragmentary due to the lack of a unique, standardized methodologic approach. Even though a significant amount of multiomics studies gave us new information about the stage-related ccRCC pathways, this knowledge needs to be corroborated by a sufficient correspondence between the findings on tissue samples and cell line samples [220–223]. To date, data presented in different studies present contradictions, and, despite evidence-based speculations describing metabolic networking, there is a lack of a comprehensive interpretation of studies.

A future perspective could be the standardization of methods used in this field of research in order to integrate and speculate deductions on standardized data through a unified approach.

Recently, the need to identify this systematization led to the publication of reviews and guides on reference materials, which are helpful as a baseline to calibrate, standardize, and compare the results obtained by different laboratories and represent an essential tool for future studies [223]. This is only the first step toward the endpoint of a unified protocol which could decrease the bias and heterogeneity risk in the methodological background.

The clinical application of this field is metabolic biomarker detection. This perspective improves disease management in diagnosis, follow-up, stage stratification, and therapeutic responsivity evaluation. However, more consistent studies on sensibility and specificity are needed to reach the point of everyday use of this biomarker.

Despite the application in different moments of disease management, the discovered impact of treatments on the metabolome of patients could lead to the use of biomarkers to assess the efficacy of the best treatment modality for metastatic stages.

Further studies are needed to validate the impact of the different treatments on the metabolic fingerprint in more extensive and independent clinical cohorts of different populations of ccRCC patients, stratified based on their ethnicity, age, sex, and staging, as well as complementing those studies with multiomics analyses to improve the accuracy in predictive biomarker detection and to give a better understanding of the mechanisms underlying cancer therapeutic resistance. In this regard, a better stratification of patients based on their metabolic fingerprints might help to predict the prognosis during the decision-making process of a pharmacological approach.

In this way, more consistent data could mean a promising clinical application in the next decade, embodying the new concept of personalized and targeted medicine.

5. Conclusions

In the last decade, an integrated approach using transcriptomics, metabolomics, and lipidomics has led to a better understanding of ccRCC as a metabolic disease. The comprehensive quantification of metabolic profiles in ccRCC patients would be an innovative strategy for choosing the optimal therapy for a specific patient. In addition, pharmacometabolomics represents a new field that could pave the way for novel stage-related and patient-tailored strategies according to the specific susceptibility to new classes of drugs. Further studies could provide a more consistent evidence-based application of this innovative perspective of disease management, improving the results in terms of OS and drug efficacy.

Author Contributions: Conceptualization, G.L.; methodology, G.L. and N.A.d.M.; software, G.L.; validation, G.L. and N.A.d.M.; formal analysis, G.L. and N.A.d.M.; investigation, G.L. and N.A.d.M.; resources, P.D. and M.B.; data curation, F.L., M.R., D.L., M.F., A.S., C.B., L.V., S.D.P., R.A., F.C., E.M., M.S.; writing—original draft preparation, G.L. and N.A.d.M.; writing—review and

editing, M.B. and P.D.; supervision, M.B. and P.D.; project administration, P.D.; funding acquisition, P.D. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer statistics, 2022. *CA Cancer J. Clin.* **2022**, *72*, 7–33. <https://doi.org/10.3322/caac.21708>.
2. Wei, J.-H.; Feng, Z.-H.; Cao, Y.; Zhao, H.-W.; Chen, Z.-H.; Liao, B.; Wang, Q.; Han, H.; Zhang, J.; Xu, Y.-Z.; et al. Predictive value of single-nucleotide polymorphism signature for recurrence in localised renal cell carcinoma: A retrospective analysis and multicentre validation study. *Lancet Oncol.* **2019**, *20*, 591–600. [https://doi.org/10.1016/S1470-2045\(18\)30932-X](https://doi.org/10.1016/S1470-2045(18)30932-X).
3. Battaglia, M.; Lucarelli, G. The role of renal surgery in the era of targeted therapy: The urologist's perspective. *Urologia* **2015**, *82*, 137–138. <https://doi.org/10.5301/uro.5000105>.
4. Di Lorenzo, G.; De Placido, S.; Pagliuca, M.; Ferro, M.; Lucarelli, G.; Rossetti, S.; Bosso, D.; Puglia, L.; Pignataro, P.; Ascione, I.; et al. The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: A systematic review. *Exp. Opin. Biol. Ther.* **2016**, *16*, 1387–1401. <https://doi.org/10.1080/14712598.2016.1216964>.
5. Tamma, R.; Rutigliano, M.; Lucarelli, G.; Annese, T.; Ruggieri, S.; Cascardi, E.; Napoli, A.; Battaglia, M.; Ribatti, D. Microvascular density, macrophages, and mast cells in human clear cell renal carcinoma with and without bevacizumab treatment. *Urol. Oncol.* **2019**, *37*, 355.e11–355.e19. <https://doi.org/10.1016/j.urolonc.2019.01.025>.
6. Testa, U.; Pelosi, E.; Castelli, G. Genetic alterations in renal cancers: Identification of the mechanisms underlying cancer initiation and progression and of therapeutic targets. *Medicines* **2020**, *7*, 44. <https://doi.org/10.3390/medicines7080044>.
7. Ragone, R.; Sallustio, F.; Piccinonna, S.; Rutigliano, M.; Vanessa, G.; Palazzo, S.; Lucarelli, G.; Dittono, P.; Battaglia, M.; Fanizzi, F.P.; et al. Renal cell carcinoma: A study through NMR-based metabolomics combined with transcriptomics. *Diseases* **2016**, *4*, 7. <https://doi.org/10.3390/diseases4010007>.
8. Forbes, S.A.; Beare, D.; Boutselakis, H.; Bamford, S.; Bindal, N.; Tate, J.; Cole, C.G.; Ward, S.; Dawson, E.; Ponting, L.; et al. COSMIC: Somatic cancer genetics at high-resolution. *Nucleic Acids Res.* **2017**, *45*(D1), D777–D783. <https://doi.org/10.1093/nar/gkw1121>.
9. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. *Nature* **2013**, *499*, 43–49. <https://doi.org/10.1038/nature12222>.
10. Gnarr, J.; Tory, K.; Weng, Y.; Schmidt, L.; Wei, M.; Li, H.; Latif, F.; Liu, S.; Chen, F.; Duh, F.-M.; et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. *Nat. Genet.* **1994**, *7*, 85–90. <https://doi.org/10.1038/ng0594-85>.
11. Mehdi, A.; Riazalhosseini, Y. Epigenome aberrations: Emerging driving factors of the clear cell renal cell carcinoma. *Int. J. Mol. Sci.* **2017**, *18*, 1774. <https://doi.org/10.3390/ijms18081774>.
12. Hakimi, A.A.; Voss, M.H. Genomic classifiers in renal cell carcinoma. *Eur. Urol.* **2018**, *73*, 770–771. <https://doi.org/10.1016/j.eururo.2018.01.013>.
13. Hakimi, A.A.; Pham, C.G.; Hsieh, J.J. A clear picture of renal cell carcinoma. *Nat. Genet.* **2013**, *45*, 849–850. <https://doi.org/10.1038/ng.2708>.
14. Sato, Y.; Yoshizato, T.; Shiraishi, Y.; Maekawa, S.; Okuno, Y.; Kamura, T.; Shimamura, T.; Sato-Otsubo, A.; Nagae, G.; Suzuki, H.; et al. Integrated molecular analysis of clear-cell renal cell carcinoma. *Nat. Genet.* **2013**, *45*, 860–867. <https://doi.org/10.1038/ng.2699>.
15. Cerami, E.; Gao, J.; Dogrusoz, U.; Gross, B.E.; Sumer, S.O.; Aksoy, B.A.; Jacobsen, A.; Byrne, C.J.; Heuer, M.L.; Larsson, E.; et al. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. *Cancer Discov.* **2012**, *2*, 401–404. Correction: *Cancer Discov.* **2012**, *2*, 960 <https://doi.org/10.1158/2159-8290.CD-12-0095>.
16. Gao, J.; Aksoy, B.A.; Dogrusoz, U.; Dresdner, G.; Gross, B.E.; Sumer, S.O.; Sun, Y.; Jacobsen, A.; Sinha, R.; Larsson, E.; et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Sci. Signal.* **2013**, *6*, p11. <https://doi.org/10.1126/scisignal.2004088>.
17. Kim, H.S.; Kim, J.H.; Jang, H.J.; Han, B.; Zang, D.Y. Clinicopathologic significance of VHL gene alteration in clear-cell renal cell carcinoma: An updated meta-analysis and review. *Int. J. Mol. Sci.* **2018**, *19*, 2529. <https://doi.org/10.3390/ijms19092529>.
18. Fan, D.; Liu, Q.; Wu, F.; Liu, N.; Qu, H.; Yuan, Y.; Li, Y.; Gao, H.; Ge, J.; Xu, Y.; et al. Prognostic significance of PI3K/AKT/ mTOR signaling pathway members in clear cell renal cell carcinoma. *PeerJ* **2020**, *8*, e9261. <https://doi.org/10.7717/peerj.9261>.
19. Guo, H.; German, P.; Bai, S.; Barnes, S.; Guo, W.; Qi, X.; Lou, H.; Liang, J.; Jonasch, E.; Mills, G.B.; et al. The PI3K/AKT pathway and renal cell carcinoma. *J. Genet. Genom.* **2015**, *42*, 343–353. <https://doi.org/10.1016/j.jgg.2015.03.003>.

20. Makhov, P.; Joshi, S.; Ghatalia, P.; Kutikov, A.; Uzzo, R.G.; Kolenko, V.M. Resistance to systemic therapies in clear cell renal cell carcinoma: Mechanisms and management strategies. *Mol. Cancer Ther.* **2018**, *17*, 1355–1364. <https://doi.org/10.1158/1535-7163.MCT-17-1299>.
21. Zhang, J.; Zhang, Q. VHL and hypoxia signaling: Beyond HIF in cancer. *Biomedicines* **2018**, *6*, 35. <https://doi.org/10.3390/biomedicines6010035>.
22. Sanchez, D.J.; Simon, M.C. Genetic and metabolic hallmarks of clear cell renal cell carcinoma. *Biochim. Biophys. Acta Rev. Cancer* **2018**, *1870*, 23–31. <https://doi.org/10.1016/j.bbcan.2018.06.003>.
23. Büscheck, F.; Fraune, C.; Simon, R.; Kluth, M.; Hube-Magg, C.; Möller-Koop, C.; Sarper, I.; Ketterer, K.; Henke, T.; Eichelberg, C.; et al. Prevalence and clinical significance of VHL mutations and 3p25 deletions in renal tumor subtypes. *Oncotarget* **2020**, *11*, 237–249. <https://doi.org/10.18632/oncotarget.27428>.
24. van de Pol, J.A.A.; Ferronika, P.; Westers, H.; van Engeland, M.; Terpstra, M.M.; Smits, K.M.; de Lange, K.; Brandt, P.A.V.D.; Sijmons, R.H.; Schouten, L.J.; et al. Evaluation of a seven gene mutational profile as a prognostic factor in a population-based study of clear cell renal cell carcinoma. *Sci. Rep.* **2022**, *12*, 6478. <https://doi.org/10.1038/s41598-022-10455-x>.
25. Shim, E.-H.; Livi, C.B.; Rakheja, D.; Tan, J.; Benson, D.; Parekh, V.; Kho, E.-Y.; Ghosh, A.P.; Kirkman, R.; Velu, S.; et al. L-2-hydroxyglutarate: An epigenetic modifier and putative oncometabolite in renal cancer. *Cancer Discov.* **2014**, *4*, 1290–1298. <https://doi.org/10.1158/2159-8290.CD-13-0696>.
26. Vavallo, A.; Simone, S.; Lucarelli, G.; Rutigliano, M.; Galleggiante, V.; Grandaliano, G.; Gesualdo, L.; Campagna, M.; Cariello, M.; Ranieri, E.; et al. Pre-existing type 2 diabetes mellitus is an independent risk factor for mortality and progression in patients with renal cell carcinoma. *Medicine* **2014**, *93*, e183. <https://doi.org/10.1097/MD.0000000000000183>.
27. Lucarelli, G.; Galleggiante, V.; Rutigliano, M.; Vavallo, A.; Ditunno, P.; Battaglia, M. Isolation and characterization of cancer stem cells in renal cell carcinoma. *Urologia* **2015**, *82*, 46–53. <https://doi.org/10.5301/uro.5000099>.
28. Galleggiante, V.; Rutigliano, M.; Sallustio, F.; Ribatti, D.; Ditunno, P.; Bettocchi, C.; Selvaggi, F.P.; Lucarelli, G.; Battaglia, M. CTR2 identifies a population of cancer cells with stem cell-like features in patients with clear cell renal cell carcinoma. *J. Urol.* **2014**, *192*, 1831–1841. <https://doi.org/10.1016/j.juro.2014.06.070>.
29. Breda, A.; Lucarelli, G.; Rodriguez-Faba, O.; Guirado, L.; Facundo, C.; Bettocchi, C.; Gesualdo, L.; Castellano, G.; Grandaliano, G.; Battaglia, M.; et al. Clinical and pathological outcomes of renal cell carcinoma (RCC) in native kidneys of patients with end-stage renal disease: A long-term comparative retrospective study with RCC diagnosed in the general population. *World J. Urol.* **2015**, *33*, 1–7. Correction: *World J. Urol.* **2015**, *33*, 9. <https://doi.org/10.1007/s00345-014-1248-y>.
30. Pandolfo, S.D.; Carbonara, U.; Beksac, A.T.; Derweesh, I.; Celia, A.; Schiavina, R.; Elbich, J.; Basile, G.; Hampton, L.J.; Cerrato, C.; et al. Microwave versus cryoablation and radiofrequency ablation for small renal mass: A multicenter comparative analysis. *Minerva Urol. Nephrol.* **2022**, *ahead of print*. <https://doi.org/10.23736/S2724-6051.22.05092-3>.
31. Pandolfo, S.D.; Loizzo, D.; Beksac, A.T.; Derweesh, I.; Celia, A.; Bianchi, L.; Elbich, J.; Costa, G.; Carbonara, U.; Lucarelli, G.; et al. Percutaneous thermal ablation for cT1 renal mass in solitary kidney: A multicenter trifecta comparative analysis versus robot-assisted partial nephrectomy. *Eur. J. Surg. Oncol.* **2022**, *ahead of print*. <https://doi.org/10.1016/j.ejso.2022.09.022>.
32. Zhang, H.; Yu, L.; Chen, J.; Liu, L.; Yang, X.; Cui, H.; Yue, G. Role of metabolic reprogramming of long non-coding RNA in clear cell renal cell carcinoma. *J. Cancer* **2022**, *13*, 691–705. <https://doi.org/10.7150/jca.62683>.
33. Lucarelli, G.; Loizzo, D.; Franzin, R.; Battaglia, S.; Ferro, M.; Cantiello, F.; Castellano, G.; Bettocchi, C.; Ditunno, P.; Battaglia, M. Metabolomic insights into pathophysiological mechanisms and biomarker discovery in clear cell renal cell carcinoma. *Exp. Rev. Mol. Diagn.* **2019**, *19*, 397–407. <https://doi.org/10.1080/14737159.2019.1607729>.
34. De la Cruz-López, K.G.; Castro-Muñoz, L.J.; Reyes-Hernández, D.O.; García-Carrancá, A.; Manzo-Merino, J. Lactate in the regulation of tumor microenvironment and therapeutic approaches. *Front. Oncol.* **2019**, *9*, 1143. <https://doi.org/10.3389/fonc.2019.01143>.
35. Wang, L.; Xiong, H.; Wu, F.; Zhang, Y.; Wang, J.; Zhao, L.; Guo, X.; Chang, L.-J.; Zhang, Y.; You, M.J.; et al. Hexokinase 2-mediated Warburg effect is required for PTEN- and p53-deficiency-driven prostate cancer growth. *Cell Rep.* **2014**, *8*, 1461–1474. <https://doi.org/10.1016/j.celrep.2014.07.053>.
36. Mayer, A.; Schmidt, M.; Seeger, A.; Serras, A.F.; Vaupel, P.; Schmidberger, H. GLUT-1 expression is largely unrelated to both hypoxia and the Warburg phenotype in squamous cell carcinomas of the vulva. *BMC Cancer* **2014**, *14*, 760. <https://doi.org/10.1186/1471-2407-14-760>.
37. Fantin, V.R.; St-Pierre, J.; Leder, P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. *Cancer Cell.* **2006**, *9*, 425–434. Correction: *Cancer Cell.* **2006**, *10*, 172. <https://doi.org/10.1016/j.ccr.2006.04.023>.
38. Shim, H.; Dolde, C.; Lewis, B.C.; Wu, C.-S.; Dang, G.; Jungmann, R.A.; Dalla-Favera, R.; Dang, C.V. c-Myc transactivation of LDH-A: Implications for tumor metabolism and growth. *Proc. Natl. Acad. Sci. USA* **1997**, *94*, 6658–6663. <https://doi.org/10.1073/pnas.94.13.6658>.
39. Johnson, R.F.; Perkins, N.D. Nuclear factor- κ B, p53, and mitochondria: Regulation of cellular metabolism and the Warburg effect. *Trends Biochem. Sci.* **2012**, *37*, 317–324. <https://doi.org/10.1016/j.tibs.2012.04.002>.
40. Lu, H.; Forbes, R.A.; Verma, A. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. *J. Biol. Chem.* **2002**, *277*, 23111–23115. <https://doi.org/10.1074/jbc.M202487200>.

41. Ward, P.S.; Thompson, C.B. Metabolic reprogramming: A cancer hallmark even Warburg did not anticipate. *Cancer Cell*. **2012**, *21*, 297–308. <https://doi.org/10.1016/j.ccr.2012.02.014>.
42. Warburg, O. On respiratory impairment in cancer cells. *Science* **1956**, *124*, 269–270.
43. Warburg, O. On the origin of cancer cells. *Science* **1956**, *123*, 309–314. <https://doi.org/10.1126/science.123.3191.309>.
44. San-Millán, I.; Brooks, G.A. Reexamining cancer metabolism: Lactate production for carcinogenesis could be the purpose and explanation of the Warburg Effect. *Carcinogenesis* **2017**, *38*, 119–133. <https://doi.org/10.1093/carcin/bgw127>.
45. Doherty, J.R.; Cleveland, J.L. Targeting lactate metabolism for cancer therapeutics. *J. Clin. Investig.* **2013**, *123*, 3685–3692. <https://doi.org/10.1172/JCI69741>.
46. Lucarelli, G.; Galleggiante, V.; Rutigliano, M.; Sanguedolce, F.; Cagiano, S.; Bufo, P.; Lastilla, G.; Maiorano, E.; Ribatti, D.; Giglio, A.; et al. Metabolomic profile of glycolysis and the pentose phosphate pathway identifies the central role of glucose-6-phosphate dehydrogenase in clear cell-renal cell carcinoma. *Oncotarget* **2015**, *6*, 13371–13386. <https://doi.org/10.18632/oncotarget.3823>.
47. Gao, H.; Dong, B.; Jia, J.; Zhu, H.; Diao, C.; Yan, Z.; Huang, Y.; Li, X. Application of ex vivo ¹H NMR metabonomics to the characterization and possible detection of renal cell carcinoma metastases. *J. Cancer Res. Clin. Oncol.* **2012**, *138*, 753–761. <https://doi.org/10.1007/s00432-011-1134-6>.
48. Dong, B.; Gao, Y.; Kang, X.; Gao, H.; Zhang, J.; Guo, H.; You, M.J.; Xue, W.; Cheng, J.; Huang, Y. SENP1 promotes proliferation of clear cell renal cell carcinoma through activation of glycolysis. *Oncotarget* **2016**, *7*, 80435–80449. <https://doi.org/10.18632/oncotarget.12606>.
49. Lucarelli, G.; Ferro, M.; Loizzo, D.; Bianchi, C.; Terracciano, D.; Cantiello, F.; Bell, L.N.; Battaglia, S.; Porta, C.; Gernone, A.; et al. Integration of lipidomics and transcriptomics reveals reprogramming of the lipid metabolism and composition in clear cell renal cell carcinoma. *Metabolites* **2020**, *10*, 509. <https://doi.org/10.3390/metabo10120509>.
50. Saito, K.; Arai, E.; Maekawa, K.; Ishikawa, M.; Fujimoto, H.; Taguchi, R.; Matsumoto, K.; Kanai, Y.; Saito, Y. Lipidomic signatures and associated transcriptomic profiles of clear cell renal cell carcinoma. *Sci. Rep.* **2016**, *6*, 28932. <https://doi.org/10.1038/srep28932>.
51. Lucarelli, G.; Rutigliano, M.; Ferro, M.; Giglio, A.; Intini, A.; Triggiano, F.; Palazzo, S.; Gigante, M.; Castellano, G.; Ranieri, E.; et al. Activation of the kynurenine pathway predicts poor outcome in patients with clear cell renal cell carcinoma. *Urol Oncol.* **2017**, *35*, 461.e15–461.e27. <https://doi.org/10.1016/j.urolonc.2017.02.011>.
52. Liu, X.; Zhang, M.; Liu, X.; Sun, H.; Guo, Z.; Tang, X.; Wang, Z.; Li, J.; Li, H.; Sun, W.; et al. Urine metabolomics for renal cell carcinoma (RCC) prediction: Tryptophan metabolism as an important pathway in RCC. *Front. Oncol.* **2019**, *9*, 663. <https://doi.org/10.3389/fonc.2019.00663>.
53. Certo, M.; Tsai, C.H.; Pucino, V.; Ho, P.C.; Mauro, C. Lactate modulation of immune responses in inflammatory versus tumour microenvironments. *Nat. Rev. Immunol.* **2021**, *21*, 151–161. <https://doi.org/10.1038/s41577-020-0406-2>.
54. Hirschhaeuser, F.; Sattler, U.G.; Mueller-Klieser, W. Lactate: A metabolic key player in cancer. *Cancer Res.* **2011**, *71*, 6921–6925. <https://doi.org/10.1158/0008-5472.CAN-11-1457>.
55. Ippolito, L.; Morandi, A.; Giannoni, E.; Chiarugi, P. Lactate: A metabolic driver in the tumour landscape. *Trends Biochem. Sci.* **2019**, *44*, 153–166. <https://doi.org/10.1016/j.tibs.2018.10.011>.
56. Zhao, J.; Huang, X.; Xu, Z.; Dai, J.; He, H.; Zhu, Y.; Wang, H. LDHA promotes tumor metastasis by facilitating epithelial-mesenchymal transition in renal cell carcinoma. *Mol. Med. Rep.* **2017**, *16*, 8335–8344. <https://doi.org/10.3892/mmr.2017.7637>.
57. Girgis, H.; Masui, O.; White, N.M.; Scorilas, A.; Rotondo, F.; Seivwright, A.; Gabril, M.; Filter, E.R.; Girgis, A.H.; Bjarnason, G.; et al. Lactate dehydrogenase A is a potential prognostic marker in clear cell renal cell carcinoma. *Mol. Cancer* **2014**, *13*, 101. <https://doi.org/10.1186/1476-4598-13-101>.
58. Sun, Z.; Tao, W.; Guo, X.; Jing, C.; Zhang, M.; Wang, Z.; Kong, F.; Suo, N.; Jiang, S.; Wang, H. Construction of a lactate-related prognostic signature for predicting prognosis, tumor microenvironment, and immune response in kidney renal clear cell carcinoma. *Front. Immunol.* **2022**, *13*, 818984. <https://doi.org/10.3389/fimmu.2022.818984>.
59. Popa, F.I.; Perlini, S.; Teofoli, F.; Degani, D.; Funghini, S.; La Marca, G.; Rinaldo, P.; Vincenzi, M.; Antoniazzi, F.; Boner, A.; et al. 3-hydroxyacyl-coenzyme a dehydrogenase deficiency: Identification of a new mutation causing hyperinsulinemic hypoketotic hypoglycemia, altered organic acids and acylcarnitines concentrations. *JIMD Rep.* **2012**, *2*, 71–77. https://doi.org/10.1007/8904_2011_50.
60. Wei, J.; Xie, Q.; Liu, X.; Wan, C.; Wu, W.; Fang, K.; Yao, Y.; Cheng, P.; Deng, D.; Liu, Z. Identification the prognostic value of glutathione peroxidases expression levels in acute myeloid leukemia. *Ann. Transl. Med.* **2020**, *8*, 678. <https://doi.org/10.21037/atm-20-3296>.
61. Ren, J.; Feng, J.; Song, W.; Wang, C.; Ge, Y.; Fu, T. Development and validation of a metabolic gene signature for predicting overall survival in patients with colon cancer. *Clin. Exp. Med.* **2020**, *20*, 535–544. <https://doi.org/10.1007/s10238-020-00652-1>.
62. Shen, C.; Song, Y.-H.; Xie, Y.; Wang, X.; Wang, Y.; Wang, C.; Liu, S.; Xue, S.-L.; Li, Y.; Liu, B.; et al. Downregulation of HADH promotes gastric cancer progression via Akt signaling pathway. *Oncotarget* **2017**, *8*, 76279–76289. <https://doi.org/10.18632/oncotarget.19348>.
63. Jiang, H.; Chen, H.; Wan, P.; Chen, N. Decreased expression of HADH is related to poor prognosis and immune infiltration in kidney renal clear cell carcinoma. *Genomics* **2021**, *113*, 3556–3564. <https://doi.org/10.1016/j.ygeno.2021.08.008>.

64. Guillem, V.; Hernández-Boluda, J.C.; Gallardo, D.; Buño, I.; Bosch, A.; Martínez-Laperche, C.; de la Cámara, R.; Brunet, S.; Martín, C.; Nieto, J.B.; et al. A polymorphism in the TYMP gene is associated with the outcome of HLA-identical sibling allogeneic stem cell transplantation. *Am. J. Hematol.* **2013**, *88*, 883–889. <https://doi.org/10.1002/ajh.23523>.
65. Li, W.; Yue, H. Thymidine phosphorylase: A potential new target for treating cardiovascular disease. *Trends Cardiovasc. Med.* **2018**, *28*, 157–171. <https://doi.org/10.1016/j.tcm.2017.10.003>.
66. Slager, E.H.; Honders, M.W.; van der Meijden, E.D.; van Luxemburg-Heijs, S.A.P.; Kloosterboer, F.M.; Kester, M.G.D.; Jedema, I.; Marijt, W.A.E.; Schaafsma, M.R.; Willemze, R.; et al. Identification of the angiogenic endothelial-cell growth factor-1/thymidine phosphorylase as a potential target for immunotherapy of cancer. *Blood* **2006**, *107*, 4954–4960. <https://doi.org/10.1182/blood-2005-09-3883>.
67. Semenza, G.L. Tumor metabolism: Cancer cells give and take lactate. *J. Clin. Investig.* **2008**, *118*, 3835–3837. <https://doi.org/10.1172/JCI37373>.
68. Miranda-Gonçalves, V.; Lameirinhas, A.; Macedo-Silva, C.; Lobo, J.; Dias, P.C.; Ferreira, V.; Henrique, R.; Jerónimo, C. Lactate increases renal cell carcinoma aggressiveness through sirtuin 1-dependent epithelial mesenchymal transition axis regulation. *Cells* **2020**, *9*, 1053. <https://doi.org/10.3390/cells9041053>.
69. Serrano-Gomez, S.J.; Maziveyi, M.; Alahari, S.K. Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications. *Mol. Cancer* **2016**, *15*, 18. <https://doi.org/10.1186/s12943-016-0502-x>.
70. Peixoto, P.; Etcheverry, A.; Aubry, M.; Missey, A.; Lachat, C.; Perrard, J.; Hendrick, E.; Delage-Mourroux, R.; Mosser, J.; Borg, C.; et al. EMT is associated with an epigenetic signature of ECM remodeling genes. *Cell Death Dis.* **2019**, *10*, 205. <https://doi.org/10.1038/s41419-019-1397-4>.
71. Potaczek, D.P.; Miethe, S.; Schindler, V.; Alhamdan, F.; Garn, H. Role of airway epithelial cells in the development of different asthma phenotypes. *Cell Signal.* **2020**, *69*, 109523. <https://doi.org/10.1016/j.cellsig.2019.109523>.
72. Simic, P.; Williams, E.O.; Bell, E.L.; Gong, J.J.; Bonkowski, M.; Guarente, L. SIRT1 suppresses the epithelial-to-mesenchymal transition in cancer metastasis and organ fibrosis. *Cell Rep.* **2013**, *3*, 1175–1186. <https://doi.org/10.1016/j.celrep.2013.03.019>.
73. Avalos, J.L.; Bever, K.M.; Wolberger, C. Mechanism of sirtuin inhibition by nicotinamide: Altering the NAD⁺ cosubstrate specificity of a Sir2 enzyme. *Mol. Cell* **2005**, *17*, 855–868. <https://doi.org/10.1016/j.molcel.2005.02.022>.
74. Yang, Y.-C.; Piek, E.; Zavadil, J.; Liang, D.; Xie, D.; Heyer, J.; Pavlidis, P.; Kucherlapati, R.; Roberts, A.B.; Böttinger, E.P. Hierarchical model of gene regulation by transforming growth factor beta. *Proc. Natl. Acad. Sci. USA* **2003**, *100*, 10269–10274. <https://doi.org/10.1073/pnas.1834070100>.
75. Rasti, A.; Madjd, Z.; Zanjani, L.S.; Babashah, S.; Abolhasani, M.; Asgari, M.; Mehrazma, M. SMAD4 expression in renal cell carcinomas correlates with a stem-cell phenotype and poor clinical outcomes. *Front. Oncol.* **2021**, *11*, 581172. <https://doi.org/10.3389/fonc.2021.581172>.
76. Lichner, Z.; Mejia-Guerrero, S.; Ignacak, M.; Krizova, A.; Bao, T.T.; Girgis, A.H.; Youssef, Y.M.; Yousef, G.M. Pleiotropic action of renal cell carcinoma-dysregulated miRNAs on hypoxia-related signaling pathways. *Am. J. Pathol.* **2012**, *180*, 1675–1687. <https://doi.org/10.1016/j.ajpath.2011.12.030>.
77. Dasgupta, P.; Kulkarni, P.; Majid, S.; Shahryari, V.; Hashimoto, Y.; Bhat, N.S.; Shiina, M.; Deng, G.; Saini, S.; Tabatabai, Z.L.; et al. MicroRNA-203 inhibits long noncoding RNA HOTAIR and regulates tumorigenesis through epithelial-to-mesenchymal transition pathway in renal cell carcinoma. *Mol. Cancer Ther.* **2018**, *17*, 1061–1069. <https://doi.org/10.1158/1535-7163.MCT-17-0925>.
78. Katayama, H.; Tamai, K.; Shibuya, R.; Nakamura, M.; Mochizuki, M.; Yamaguchi, K.; Kawamura, S.; Tochigi, T.; Sato, I.; Okanishi, T.; et al. Long non-coding RNA HOTAIR promotes cell migration by upregulating insulin growth factor-binding protein 2 in renal cell carcinoma. *Sci. Rep.* **2017**, *7*, 12016. <https://doi.org/10.1038/s41598-017-12191-z>.
79. Ozcan, A.; Shen, S.S.; Zhai, Q.J.; Truong, L.D. Expression of GLUT1 in primary renal tumors: Morphologic and biologic implications. *Am. J. Clin. Pathol.* **2007**, *128*, 245–254. <https://doi.org/10.1309/HV6NJVQRQKK4QHM9F>.
80. Singer, K.; Kastenberger, M.; Gottfried, E.; Hammerschmied, C.G.; Büttner, M.; Aigner, M.; Seliger, B.; Walter, B.; Schlösser, H.; Hartmann, A.; et al. Warburg phenotype in renal cell carcinoma: High expression of glucose-transporter 1 (GLUT-1) correlates with low CD8⁺ T-cell infiltration in the tumor. *Int. J. Cancer* **2011**, *128*, 2085–2095. <https://doi.org/10.1002/ijc.25543>.
81. Fischer, K.; Hoffmann, P.; Voelkl, S.; Meidenbauer, N.; Ammer, J.; Edinger, M.; Gottfried, E.; Schwarz, S.; Rothe, G.; Hoves, S.; et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. *Blood* **2007**, *109*, 3812–3819. <https://doi.org/10.1182/blood-2006-07-035972>.
82. Miyakita, H.; Tokunaga, M.; Onda, H.; Usui, Y.; Kinoshita, H.; Kawamura, N.; Yasuda, S. Significance of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT-1) expression in the cancer. *Int. J. Urol.* **2002**, *9*, 15–18. <https://doi.org/10.1046/j.1442-2042.2002.00416.x>.
83. Kobayashi, M.; Uematsu, T.; Tokura, Y.; Takei, K.; Sakamoto, K.; Narimatsu, T.; Nukui, A.; Kamai, T. Immunohistochemical expression of sodium-dependent glucose transporter-2 (SGLT-2) in clear cell renal carcinoma: Possible prognostic implications. *Int. Braz. J. Urol.* **2019**, *45*, 169–178. <https://doi.org/10.1590/S1677-5538.IBJU.2018.0271>.

84. Linden, K.C.; DeHaan, C.L.; Zhang, Y.; Glowacka, S.; Cox, A.J.; Kelly, D.J.; Rogers, S. Renal expression and localization of the facilitative glucose transporters GLUT1 and GLUT12 in animal models of hypertension and diabetic nephropathy. *Am. J. Physiol. Renal Physiol.* **2006**, *290*, F205–F213. <https://doi.org/10.1152/ajprenal.00237.2004>.
85. Ishikawa, N.; Oguri, T.; Isobe, T.; Fujitaka, K.; Kohno, N. SGLT gene expression in primary lung cancers and their metastatic lesions. *Jpn. J. Cancer Res.* **2001**, *92*, 874–879. <https://doi.org/10.1111/j.1349-7006.2001.tb01175.x>.
86. Helmke, B.M.; Reisser, C.; Idzko, M.; Dyckhoff, G.; Herold-Mende, C. Expression of SGLT-1 in preneoplastic and neoplastic lesions of the head and neck. *Oral. Oncol.* **2004**, *40*, 28–35. Erratum in *Oral. Oncol.* **2004**, *40*, 654. [https://doi.org/10.1016/s1368-8375\(03\)00129-5](https://doi.org/10.1016/s1368-8375(03)00129-5).
87. Casneuf, V.F.; Fonteyne, P.; Van Damme, N.; Demetter, P.; Pauwels, P.; De Hemptinne, B.; De Vos, M.; Van De Wiele, C.; Peeters, M. Expression of SGLT1, Bcl-2 and p53 in primary pancreatic cancer related to survival. *Cancer Investig.* **2008**, *26*, 852–859. <https://doi.org/10.1080/07357900801956363>.
88. Perez, M.; Praena-Fernandez, J.M.; Felipe-Abrio, B.; Lopez-García, M.A.; Lucena-Cacace, A.; Garcia, A.; Lleonart, M.; Roncador, G.; Marin, J.J.; Carnero, A. MAP17 and SGLT1 protein expression levels as prognostic markers for cervical tumor patient survival. *PLoS ONE* **2013**, *8*, e56169. <https://doi.org/10.1371/journal.pone.0056169>.
89. Lai, B.; Xiao, Y.; Pu, H.; Cao, Q.; Jing, H.; Liu, X. Overexpression of SGLT1 is correlated with tumor development and poor prognosis of ovarian carcinoma. *Arch. Gynecol. Obstet.* **2012**, *285*, 1455–1461. <https://doi.org/10.1007/s00404-011-2166-5>.
90. Guo, G.F.; Cai, Y.C.; Zhang, B.; Xu, R.H.; Qiu, H.J.; Xia, L.P.; Jiang, W.Q.; Hu, P.L.; Chen, X.X.; Zhou, F.F.; et al. Overexpression of SGLT1 and EGFR in colorectal cancer showing a correlation with the prognosis. *Med. Oncol.* **2011**, *28* (Suppl. 1), S197–S203. <https://doi.org/10.1007/s12032-010-9696-8>.
91. Scafoglio, C.; Hirayama, B.A.; Kepe, V.; Liu, J.; Ghezzi, C.; Satyamurthy, N.; Moatamed, N.A.; Huang, J.; Koepsell, H.; Barrio, J.R.; et al. Functional expression of sodium-glucose transporters in cancer. *Proc. Natl. Acad. Sci. USA* **2015**, *112*, E4111–E4119. <https://doi.org/10.1073/pnas.1511698112>.
92. Kim, Y.; Choi, J.W.; Lee, J.H.; Kim, Y.S. Expression of lactate/H⁺ symporters MCT1 and MCT4 and their chaperone CD147 predicts tumor progression in clear cell renal cell carcinoma: Immunohistochemical and The Cancer Genome Atlas data analyses. *Hum. Pathol.* **2015**, *46*, 104–112. <https://doi.org/10.1016/j.humpath.2014.09.013>.
93. Fisel, P.; Kruck, S.; Winter, S.; Bedke, J.; Hennenlotter, J.; Nies, A.T.; Scharpf, M.; Fend, F.; Stenzl, A.; Schwab, M.; et al. DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome. *Clin. Cancer Res.* **2013**, *19*, 5170–5181. <https://doi.org/10.1158/1078-0432.CCR-13-1180>.
94. Pinheiro, C.; Longatto-Filho, A.; Ferreira, L.; Pereira, S.M.M.; Etlinger, D.; Moreira, M.A.R.; Jubé, L.F.; Queiroz, G.S.; Schmitt, F.; Baltazar, F. Increasing expression of monocarboxylate transporters 1 and 4 along progression to invasive cervical carcinoma. *Int. J. Gynecol. Pathol.* **2008**, *27*, 568–574. <https://doi.org/10.1097/PGP.0b013e31817b5b40>.
95. Yoo, A.; Lee, H.; Jung, J.; Koh, S.S.; Lee, S. Monocarboxylate transporter 9 (MCT9) is down-regulated in renal cell carcinoma. *Genes Genom.* **2021**, *43*, 351–359. <https://doi.org/10.1007/s13258-020-01035-2>.
96. Ichida, K.; Matsuo, H.; Takada, T.; Nakayama, A.; Murakami, K.; Shimizu, T.; Yamanashi, Y.; Kasuga, H.; Nakashima, H.; Nakamura, T.; et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia. *Nat. Commun.* **2012**, *3*, 764. <https://doi.org/10.1038/ncomms1756>.
97. Yang, H.-C.; Wu, Y.-H.; Yen, W.-C.; Liu, H.-Y.; Hwang, T.-L.; Stern, A.; Chiu, D.T.-Y. The redox role of G6PD in cell growth, cell death, and cancer. *Cells* **2019**, *8*, 1055. <https://doi.org/10.3390/cells8091055>.
98. Song, J.; Sun, H.; Zhang, S.; Shan, C. The multiple roles of glucose-6-phosphate dehydrogenase in tumorigenesis and cancer chemoresistance. *Life* **2022**, *12*, 271. <https://doi.org/10.3390/life12020271>.
99. Zhang, Q.; Yang, Z.; Han, Q.; Bai, H.; Wang, Y.; Yi, X.; Yi, Z.; Yang, L.; Jiang, L.; Song, X.; et al. G6PD promotes renal cell carcinoma proliferation through positive feedback regulation of p-STAT3. *Oncotarget* **2017**, *8*, 109043–109060. <https://doi.org/10.18632/oncotarget.22566>.
100. Fan, T.-F.; Wu, T.-F.; Bu, L.-L.; Ma, S.-R.; Li, Y.-C.; Mao, L.; Sun, Z.-J.; Zhang, W.-F. Dihydropyridin promotes autophagy and apoptosis through ROS-STAT3 signaling in head and neck squamous cell carcinoma. *Oncotarget* **2016**, *7*, 59691–59703. <https://doi.org/10.18632/oncotarget.10836>.
101. Morgan, M.J.; Liu, Z.G. Crosstalk of reactive oxygen species and NF- κ B signaling. *Cell Res.* **2011**, *21*, 103–115. <https://doi.org/10.1038/cr.2010.178>.
102. Li, G.; Liao, Y.; Hu, J.; Lu, L.; Zhang, Y.; Li, B.; An, T. Activation of NF- κ B pathways mediating the inflammation and pulmonary diseases associated with atmospheric methylamine exposure. *Environ. Pollut.* **2019**, *252* (Pt. B), 1216–1224. <https://doi.org/10.1016/j.envpol.2019.06.059>.
103. Grivennikov, S.I.; Karin, M. Dangerous liaisons: STAT3 and NF- κ B collaboration and crosstalk in cancer. *Cytokine Growth Factor Rev.* **2010**, *21*, 11–19. <https://doi.org/10.1016/j.cytogfr.2009.11.005>.
104. Kim, E.K.; Jang, M.; Song, M.J.; Kim, D.; Kim, Y.; Jang, H.H. Redox-mediated mechanism of chemoresistance in cancer cells. *Antioxidants* **2019**, *8*, 471. <https://doi.org/10.3390/antiox8100471>.
105. Xian, D.; Lai, R.; Song, J.; Xiong, X.; Zhong, J. Emerging perspective: Role of increased ROS and redox imbalance in skin carcinogenesis. *Oxid. Med. Cell Longev.* **2019**, *2019*, 8127362. <https://doi.org/10.1155/2019/8127362>.
106. Yoon, S.; Woo, S.U.; Kang, J.H.; Kim, K.; Shin, H.-J.; Gwak, H.-S.; Park, S.; Chwae, Y.-J. NF- κ B and STAT3 cooperatively induce IL6 in starved cancer cells. *Oncogene* **2012**, *31*, 3467–3481. <https://doi.org/10.1038/onc.2011.517>.

107. Wang, Y.; Su, J.; Wang, Y.; Fu, D.; Ideozu, J.E.; Geng, H.; Cui, Q.; Wang, C.; Chen, R.; Yu, Y.; et al. The interaction of YBX1 with G3BP1 promotes renal cell carcinoma cell metastasis via YBX1/G3BP1-SPP1-NF- κ B signaling axis. *J. Exp. Clin. Cancer Res.* **2019**, *38*, 386. <https://doi.org/10.1186/s13046-019-1347-0>.
108. Lorente, D.; Trilla, E.; Meseguer, A.; Arevalo, J.; Nemours, S.; Planas, J.; Placer, J.; Celma, A.; Salvador, C.; Regis, L.; et al. The role of STAT3 protein as a prognostic factor in the clear cell renal carcinoma. Systematic review. Valor de la proteína STAT3 como factor pronóstico en el carcinoma renal de célula clara. Revisión sistemática. *Actas Urol. Esp. (Engl. Ed.)* **2019**, *43*, 118–123. <https://doi.org/10.1016/j.acuro.2018.08.003>.
109. Cuadros, T.; Trilla, E.; Sarró, E.; Vilà, M.R.; Vilardell, J.; de Torres, I.; Salcedo, M.; López-Hellin, J.; Sánchez, A.; Cajal, S.R.Y.; et al. HAVCR/KIM-1 activates the IL-6/STAT-3 pathway in clear cell renal cell carcinoma and determines tumor progression and patient outcome. *Cancer Res.* **2014**, *74*, 1416–1428. <https://doi.org/10.1158/0008-5472.CAN-13-1671>.
110. Lafarge, S.; Hamzeh-Cognasse, H.; Richard, Y.; Pozzetto, B.; Cogné, M.; Cognasse, F.; Garraud, O. Complexes between nuclear factor- κ B p65 and signal transducer and activator of transcription 3 are key actors in inducing activation-induced cytidine deaminase expression and immunoglobulin A production in CD40L plus interleukin-10-treated human blood B cells. *Clin. Exp. Immunol.* **2011**, *166*, 171–183. <https://doi.org/10.1111/j.1365-2249.2011.04465.x>.
111. Kim, S.J.; Yoon, S. Activated Rac1 regulates the degradation of I κ B α and the nuclear translocation of STAT3-NF κ B complexes in starved cancer cells. *Exp. Mol. Med.* **2016**, *48*, e231. <https://doi.org/10.1038/emm.2016.17>.
112. Nan, J.; Hu, H.; Sun, Y.; Zhu, L.; Wang, Y.; Zhong, Z.; Zhao, J.; Zhang, N.; Wang, Y.; Wang, Y.; et al. TNFR2 stimulation promotes mitochondrial fusion via Stat3- and NF- κ B-dependent activation of OPA1 expression. *Circ. Res.* **2017**, *121*, 392–410. <https://doi.org/10.1161/CIRCRESAHA.117.311143>.
113. Ni, Y.; Yang, Z.; Agbana, Y.L.; Bai, H.; Wang, L.; Yang, L.; Yi, Z.; Cheng, J.; Zhang, Q.; Kuang, Y.; et al. Silent information regulator 2 promotes clear cell renal cell carcinoma progression through deacetylation and small ubiquitin-related modifier 1 modification of glucose 6-phosphate dehydrogenase. *Cancer Sci.* **2021**, *112*, 4075–4086. <https://doi.org/10.1111/cas.15085>.
114. Zhang, Q.; Han, Q.; Yang, Z.; Ni, Y.; Agbana, Y.L.; Bai, H.; Yi, Z.; Yi, X.; Kuang, Y.; Zhu, Y. G6PD facilitates clear cell renal cell carcinoma invasion by enhancing MMP2 expression through ROS-MAPK axis pathway. *Int. J. Oncol.* **2020**, *57*, 197–212. <https://doi.org/10.3892/ijo.2020.5041>.
115. Burlaka, A.P.; Ganusevich, I.I.; Gafurov, M.R.; Lukin, S.M.; Sidorik, E.P. Stomach cancer: Interconnection between the redox state, activity of MMP-2, MMP-9 and stage of tumor growth. *Cancer Microenviron.* **2016**, *9*, 27–32. <https://doi.org/10.1007/s12307-016-0182-5>.
116. Zhang, Q.; Ni, Y.; Wang, S.; Agbana, Y.L.; Han, Q.; Liu, W.; Bai, H.; Yi, Z.; Yi, X.; Zhu, Y.; et al. G6PD upregulates Cyclin E1 and MMP9 to promote clear cell renal cell carcinoma progression. *Int. J. Med. Sci.* **2022**, *19*, 47–64. <https://doi.org/10.7150/ijms.58902>.
117. Gobin, E.; Bagwell, K.; Wagner, J.; Mysona, D.; Sandirasegarane, S.; Smith, N.; Bai, S.; Sharma, A.; Schleifer, R.; She, J.-X. A pan-cancer perspective of matrix metalloproteases (MMP) gene expression profile and their diagnostic/prognostic potential. *BMC Cancer* **2019**, *19*, 581. <https://doi.org/10.1186/s12885-019-5768-0>.
118. VandeKopple, M.J.; Wu, J.; Auer, E.N.; Giaccia, A.J.; Denko, N.C.; Papandreou, I. HILPDA regulates lipid metabolism, lipid droplet abundance, and response to microenvironmental stress in solid tumors. *Mol. Cancer Res.* **2019**, *17*, 2089–2101. <https://doi.org/10.1158/1541-7786.MCR-18-1343>.
119. Avgerinos, K.I.; Spyrou, N.; Mantzoros, C.S.; Dalamaga, M. Obesity and cancer risk: Emerging biological mechanisms and perspectives. *Metabolism* **2019**, *92*, 121–135. <https://doi.org/10.1016/j.metabol.2018.11.001>.
120. Petan, T.; Jarc, E.; Jusović, M. Lipid droplets in cancer: Guardians of fat in a stressful world. *Molecules* **2018**, *23*, 1941. <https://doi.org/10.3390/molecules23081941>.
121. Liu, S.; Liu, X.; Wu, F.; Zhang, X.; Zhang, H.; Gao, D.; Bi, D.; Qu, H.; Ge, J.; Xu, Y.; et al. HADHA overexpression disrupts lipid metabolism and inhibits tumor growth in clear cell renal cell carcinoma. *Exp. Cell Res.* **2019**, *384*, 111558. <https://doi.org/10.1016/j.yexcr.2019.111558>.
122. Ackerman, D.; Tumanov, S.; Qiu, B.; Michalopoulou, E.; Spata, M.; Azzam, A.; Xie, H.; Simon, M.C.; Kamphorst, J.J. Triglycerides promote lipid homeostasis during hypoxic stress by balancing fatty acid saturation. *Cell Rep.* **2018**, *24*, 2596–2605.e5. <https://doi.org/10.1016/j.celrep.2018.08.015>.
123. Boroughs, L.K.; DeBerardinis, R.J. Metabolic pathways promoting cancer cell survival and growth. *Nat. Cell Biol.* **2015**, *17*, 351–359. <https://doi.org/10.1038/ncb3124>.
124. Zhao, Z.; Lu, J.; Han, L.; Wang, X.; Man, Q.; Liu, S. Prognostic significance of two lipid metabolism enzymes, HADHA and ACAT2, in clear cell renal cell carcinoma. *Tumour Biol.* **2016**, *37*, 8121–8130. <https://doi.org/10.1007/s13277-015-4720-4>.
125. Wettersten, H.I.; Hakimi, A.A.; Morin, D.; Bianchi, C.; Johnstone, M.E.; Donohoe, D.R.; Trott, J.F.; Abu Aboud, O.; Stirdivant, S.; Neri, B.; et al. Grade-dependent metabolic reprogramming in kidney cancer revealed by combined proteomics and metabolomics analysis. *Cancer Res.* **2015**, *75*, 2541–2552. <https://doi.org/10.1158/0008-5472.CAN-14-1703>.
126. Bianchi, C.; Meregalli, C.; Bombelli, S.; Di Stefano, V.; Salerno, F.; Torsello, B.; De Marco, S.; Bovo, G.; Cifola, I.; Mangano, E.; et al. The glucose and lipid metabolism reprogramming is grade-dependent in clear cell renal cell carcinoma primary cultures and is targetable to modulate cell viability and proliferation. *Oncotarget* **2017**, *8*, 113502–113515. <https://doi.org/10.18632/oncotarget.23056>.

127. Qiu, B.; Ackerman, D.; Sanchez, D.J.; Li, B.; Ochocki, J.D.; Grazioli, A.; Bobrovnikova-Marjon, E.; Diehl, J.A.; Keith, B.; Simon, M.C. HIF2 α -dependent lipid storage promotes endoplasmic reticulum homeostasis in clear-cell renal cell carcinoma. *Cancer Discov.* **2015**, *5*, 652–667. <https://doi.org/10.1158/2159-8290.CD-14-1507>.
128. van der Mijl, J.C.; Fu, L.; Khani, F.; Zhang, T.; Molina, A.M.; Barbieri, C.E.; Chen, Q.; Gross, S.S.; Gudas, L.J.; Nanus, D.M. Combined metabolomics and genome-wide transcriptomics analyses show multiple HIF1 α -induced changes in lipid metabolism in early stage clear cell renal cell carcinoma. *Transl. Oncol.* **2020**, *13*, 177–185. <https://doi.org/10.1016/j.tranon.2019.10.015>.
129. Bombelli, S.; Torsello, B.; De Marco, S.; Lucarelli, G.; Cifola, I.; Grasselli, C.; Strada, G.; Bovo, G.; Perego, R.A.; Bianchi, C. 36-kDa annexin A3 isoform negatively modulates lipid storage in clear cell renal cell carcinoma cells. *Am. J. Pathol.* **2020**, *190*, 2317–2326. <https://doi.org/10.1016/j.ajpath.2020.08.008>.
130. Ding, X.; Zhang, W.; Li, S.; Yang, H. The role of cholesterol metabolism in cancer. *Am. J. Cancer Res.* **2019**, *9*, 219–227.
131. Go, G.W.; Mani, A. Low-density lipoprotein receptor (LDLR) family orchestrates cholesterol homeostasis. *Yale J. Biol. Med.* **2012**, *85*, 19–28.
132. Shen, W.J.; Azhar, S.; Kraemer, F.B. SR-B1: A unique multifunctional receptor for cholesterol influx and efflux. *Annu. Rev. Physiol.* **2018**, *80*, 95–116. <https://doi.org/10.1146/annurev-physiol-021317-121550>.
133. Li, F.; Zhang, H. Lysosomal acid lipase in lipid metabolism and beyond. *Arterioscler. Thromb. Vasc. Biol.* **2019**, *39*, 850–856. <https://doi.org/10.1161/ATVBAHA.119.312136>.
134. Sundelin, J.P.; Ståhlman, M.; Lundqvist, A.; Levin, M.; Parini, P.; Johansson, M.E.; Borén, J. Increased expression of the very low-density lipoprotein receptor mediates lipid accumulation in clear-cell renal cell carcinoma. *PLoS ONE* **2012**, *7*, e48694. <https://doi.org/10.1371/journal.pone.0048694>.
135. Wang, J.; Tan, M.; Ge, J.; Zhang, P.; Zhong, J.; Tao, L.; Wang, Q.; Tong, X.; Qiu, J. Lysosomal acid lipase promotes cholesterol ester metabolism and drives clear cell renal cell carcinoma progression. *Cell Prolif.* **2018**, *51*, e12452. <https://doi.org/10.1111/cpr.12452>.
136. Goldstein, J.L.; Brown, M.S. Regulation of the mevalonate pathway. *Nature* **1990**, *343*, 425–430. <https://doi.org/10.1038/343425a0>.
137. Sinensky, M. Recent advances in the study of prenylated proteins. *Biochim. Biophys. Acta* **2000**, *1484*, 93–106. [https://doi.org/10.1016/s1388-1981\(00\)00009-3](https://doi.org/10.1016/s1388-1981(00)00009-3).
138. Iannelli, F.; Lombardi, R.; Milone, M.R.; Pucci, B.; De Rienzo, S.; Budillon, A.; Bruzzese, F. Targeting mevalonate pathway in cancer treatment: Repurposing of statins. *Recent Pat. Anticancer Drug Discov.* **2018**, *13*, 184–200. <https://doi.org/10.2174/1574892812666171129141211>.
139. Misirkic, M.; Janjetovic, K.; Vucicevic, L.; Tovilovic, G.; Ristic, B.; Vilimanovich, U.; Harhaji-Trajkovic, L.; Sumarac-Dumanovic, M.; Micic, D.; Bumbasirevic, V.; et al. Inhibition of AMPK-dependent autophagy enhances in vitro anti glioma effect of simvastatin. *Pharmacol. Res.* **2012**, *65*, 111–119. <https://doi.org/10.1016/j.phrs.2011.08.003>.
140. Parikh, A.; Childress, C.; Deitrick, K.; Lin, Q.; Rukstalis, D.; Yang, W. Statin-induced autophagy by inhibition of geranylgeranyl biosynthesis in prostate cancer PC3 cells. *Prostate* **2010**, *70*, 971–981. <https://doi.org/10.1002/pros.21131>.
141. Kang, S.; Kim, E.S.; Moon, A. Simvastatin and lovastatin inhibit breast cell invasion induced by H-Ras. *Oncol. Rep.* **2009**, *21*, 1317–1322. https://doi.org/10.3892/or_00000357.
142. Goldman, M.J.; Craft, B.; Hastie, M.; Repčeka, K.; McDade, F.; Kamath, A.; Banerjee, A.; Luo, Y.; Rogers, D.; Brooks, A.N.; et al. Visualizing and interpreting cancer genomics data via the Xena platform. *Nat. Biotechnol.* **2020**, *38*, 675–678. <https://doi.org/10.1038/s41587-020-0546-8>.
143. Gebhard, R.L.; Clayman, R.V.; Prigge, W.F.; Figenschau, R.; A Staley, N.; Reesey, C.; Bear, A. Abnormal cholesterol metabolism in renal clear cell carcinoma. *J. Lipid Res.* **1987**, *28*, 1177–1184.
144. Shimano, H.; Sato, R. SREBP-regulated lipid metabolism: Convergent physiology–divergent pathophysiology. *Nat. Rev. Endocrinol.* **2017**, *13*, 710–730. <https://doi.org/10.1038/nrendo.2017.91>.
145. De la Cruz López, K.G.; Toledo Guzmán, M.E.; Sánchez, E.O.; García Carrancá, A. mTORC1 as a regulator of mitochondrial functions and a therapeutic target in cancer. *Front. Oncol.* **2019**, *9*, 1373. <https://doi.org/10.3389/fonc.2019.01373>.
146. Liu, G.; Zhao, X.; Zhou, J.; Cheng, X.; Ye, Z.; Ji, Z. LncRNA TP73-AS1 promotes cell proliferation and inhibits cell apoptosis in clear cell renal cell carcinoma through repressing KISS1 expression and inactivation of PI3K/Akt/mTOR signaling pathway. *Cell. Physiol. Biochem.* **2018**, *48*, 371–384. <https://doi.org/10.1159/000491767>.
147. Li, X.; Liu, Z.; Xia, C.; Yan, K.; Fang, Z.; Fan, Y. SETD8 stabilized by USP17 epigenetically activates SREBP1 pathway to drive lipogenesis and oncogenesis of ccRCC. *Cancer Lett.* **2022**, *527*, 150–163. <https://doi.org/10.1016/j.canlet.2021.12.018>.
148. Fang, J.; Feng, Q.; Ketel, C.S.; Wang, H.; Cao, R.; Xia, L.; Erdjument-Bromage, H.; Tempst, P.; Simon, J.A.; Zhang, Y. Purification and functional characterization of SET8, a nucleosomal histone H4-lysine 20-specific methyltransferase. *Curr. Biol.* **2002**, *12*, 1086–1099. [https://doi.org/10.1016/s0960-9822\(02\)00924-7](https://doi.org/10.1016/s0960-9822(02)00924-7).
149. Serrano, L.; Martínez-Redondo, P.; Marazuela-Duque, A.; Vazquez, B.N.; Dooley, S.J.; Voigt, P.; Beck, D.B.; Kane-Goldsmith, N.; Tong, Q.; Rabanal, R.M.; et al. The tumor suppressor SirT2 regulates cell cycle progression and genome stability by modulating the mitotic deposition of H4K20 methylation. *Genes Dev.* **2013**, *27*, 639–653. <https://doi.org/10.1101/gad.211342.112>.
150. Beck, D.B.; Oda, H.; Shen, S.S.; Reinberg, D. PR-Set7 and H4K20me1: At the crossroads of genome integrity, cell cycle, chromosome condensation, and transcription. *Genes Dev.* **2012**, *26*, 325–337. <https://doi.org/10.1101/gad.177444.111>.

151. Dulev, S.; Tkach, J.; Lin, S.; Batada, N.N. SET8 methyltransferase activity during the DNA double-strand break response is required for recruitment of 53BP1. *EMBO Rep.* **2014**, *15*, 1163–1174. <https://doi.org/10.15252/embr.201439434>.
152. de la Vega, M.; Kelvin, A.A.; Dunican, D.J.; McFarlane, C.; Burrows, J.F.; Jaworski, J.; Stevenson, N.J.; Dib, K.; Rappoport, J.Z.; Scott, C.J.; et al. The deubiquitinating enzyme USP17 is essential for GTPase subcellular localization and cell motility. *Nat. Commun.* **2011**, *2*, 259. <https://doi.org/10.1038/ncomms1243>.
153. Pereg, Y.; Liu, B.Y.; O'Rourke, K.M.; Sagolla, M.; Dey, A.; Komuves, L.; French, D.M.; Dixit, V.M. Ubiquitin hydrolase Dub3 promotes oncogenic transformation by stabilizing Cdc25A. *Nat. Cell Biol.* **2010**, *12*, 400–406. <https://doi.org/10.1038/ncb2041>.
154. Liu, T.; Yu, J.; Deng, M.; Yin, Y.; Zhang, H.; Luo, K.; Qin, B.; Li, Y.; Wu, C.; Ren, T.; et al. CDK4/6-dependent activation of DUB3 regulates cancer metastasis through SNAIL1. *Nat. Commun.* **2017**, *8*, 13923. <https://doi.org/10.1038/ncomms13923>.
155. Wu, Y.; Wang, Y.; Lin, Y.; Liu, Y.; Wang, Y.; Jia, J.; Singh, P.; Chi, Y.-I.; Wang, C.; Dong, C.; et al. Dub3 inhibition suppresses breast cancer invasion and metastasis by promoting Snail1 degradation. *Nat. Commun.* **2017**, *8*, 14228. <https://doi.org/10.1038/ncomms14228>.
156. Lin, Y.; Wang, Y.; Shi, Q.; Yu, Q.; Liu, C.; Feng, J.; Deng, J.; Evers, B.M.; Zhou, B.P.; Wu, Y. Stabilization of the transcription factors slug and twist by the deubiquitinase dub3 is a key requirement for tumor metastasis. *Oncotarget* **2017**, *8*, 75127–75140. <https://doi.org/10.18632/oncotarget.20561>.
157. Lu, C.-H.; Yeh, D.-W.; Lai, C.-Y.; Liu, Y.-L.; Huang, L.-R.; Lee, A.Y.-L.; Jin, S.-L.C.; Chuang, T.-H. USP17 mediates macrophage-promoted inflammation and stemness in lung cancer cells by regulating TRAF2/TRAF3 complex formation. *Oncogene*. **2018**, *37*, 6327–6340. Erratum in *Oncogene* **2019**, *38*, 5742–5743. <https://doi.org/10.1038/s41388-018-0411-0>.
158. Chen, X.; Wang, C.; Liao, K.; Zhou, S.; Cao, L.; Chen, J.; Xu, C.; Lin, Y. USP17 suppresses tumorigenesis and tumor growth through deubiquitinating AEP. *Int. J. Biol. Sci.* **2019**, *15*, 738–748. <https://doi.org/10.7150/ijbs.30106>.
159. McFarlane, C.; Kelvin, A.A.; de la Vega, M.; Govender, U.; Scott, C.J.; Burrows, J.F.; Johnston, J.A. The deubiquitinating enzyme USP17 is highly expressed in tumor biopsies, is cell cycle regulated, and is required for G1-S progression. *Cancer Res.* **2010**, *70*, 3329–3339. <https://doi.org/10.1158/0008-5472.CAN-09-4152>.
160. Yang, H.; Zhao, H.; Ren, Z.; Yi, X.; Zhang, Q.; Yang, Z.; Kuang, Y.; Zhu, Y. Overexpression CPT1A reduces lipid accumulation via PPAR α /CD36 axis to suppress the cell proliferation in ccRCC. *Acta Biochim. Biophys. Sin.* **2022**, *54*, 220–231. <https://doi.org/10.3724/abbs.2021023>.
161. Du, W.; Zhang, L.; Brett-Morris, A.; Aguila, B.; Kerner, J.; Hoppel, C.L.; Puchowicz, M.; Serra, D.; Herrero, L.; Rini, B.I.; et al. HIF drives lipid deposition and cancer in ccRCC via repression of fatty acid metabolism. *Nat. Commun.* **2017**, *8*, 1769. <https://doi.org/10.1038/s41467-017-01965-8>.
162. Zani, I.A.; Stephen, S.L.; Mughal, N.A.; Russell, D.; Homer-Vanniasinkam, S.; Wheatcroft, S.B.; Ponnambalam, S. Scavenger receptor structure and function in health and disease. *Cells* **2015**, *4*, 178–201. <https://doi.org/10.3390/cells4020178>.
163. Yang, Q.; Shu, F.; Gong, J.; Ding, P.; Cheng, R.; Li, J.; Tong, R.; Ding, L.; Sun, H.; Huang, W.; et al. Sweroside ameliorates NAFLD in high-fat diet induced obese mice through the regulation of lipid metabolism and inflammatory response. *J. Ethnopharmacol.* **2020**, *255*, 112556. <https://doi.org/10.1016/j.jep.2020.112556>.
164. Ou, M.; Huang, R.; Luo, Q.; Xiong, L.; Chen, K.; Wang, Y. Characterisation of scavenger receptor class B type 1 in rare minnow (*Gobiocypris rarus*). *Fish Shellfish Immunol.* **2019**, *89*, 614–622. <https://doi.org/10.1016/j.fsi.2019.04.031>.
165. Liu, G.-Z.; Hou, T.-T.; Yuan, Y.; Hang, P.-Z.; Zhao, J.-J.; Sun, L.; Zhao, G.-Q.; Dong, J.-M.; Wang, X.-B.; Shi, H.; et al. Fenofibrate inhibits atrial metabolic remodelling in atrial fibrillation through PPAR- α /sirtuin 1/PGC-1 α pathway. *Br. J. Pharmacol.* **2016**, *173*, 1095–1109. <https://doi.org/10.1111/bph.13438>.
166. Goto, T. A review of the studies on food-derived factors which regulate energy metabolism via the modulation of lipid-sensing nuclear receptors. *Biosci. Biotechnol. Biochem.* **2019**, *83*, 579–588. <https://doi.org/10.1080/09168451.2018.1559025>.
167. Song, S.; Attia, R.R.; Connaughton, S.; Niesen, M.I.; Ness, G.C.; Elam, M.B.; Hori, R.T.; Cook, G.A.; Park, E.A. Peroxisome proliferator activated receptor alpha (PPARalpha) and PPAR gamma coactivator (PGC-1alpha) induce carnitine palmitoyltransferase IA (CPT-1A) via independent gene elements. *Mol. Cell Endocrinol.* **2010**, *325*, 54–63. <https://doi.org/10.1016/j.mce.2010.05.019>.
168. Zhang, Y.; Wang, H.; Zhang, J.; Lv, J.; Huang, Y. Positive feedback loop and synergistic effects between hypoxia-inducible factor-2 α and stearoyl-CoA desaturase-1 promote tumorigenesis in clear cell renal cell carcinoma. *Cancer Sci.* **2013**, *104*, 416–422. <https://doi.org/10.1111/cas.12108>.
169. Tanaka, K.; Kandori, S.; Sakka, S.; Nitta, S.; Tanuma, K.; Shiga, M.; Nagumo, Y.; Negoro, H.; Kojima, T.; Mathis, B.J.; et al. ELOVL2 promotes cancer progression by inhibiting cell apoptosis in renal cell carcinoma. *Oncol. Rep.* **2022**, *47*, 23. <https://doi.org/10.3892/or.2021.8234>.
170. Kobayashi, T.; Zdravec, D.; Jacobsson, A. ELOVL2 overexpression enhances triacylglycerol synthesis in 3T3-L1 and F442A cells. *FEBS Lett.* **2007**, *581*, 3157–3163. <https://doi.org/10.1016/j.febslet.2007.05.081>.
171. Morris, S.M., Jr. Arginine: Beyond protein. *Am. J. Clin. Nutr.* **2006**, *83*, 508S–512S. <https://doi.org/10.1093/ajcn/83.2.508S>.
172. Keshet, R.; Szlosarek, P.; Carracedo, A.; Erez, A. Rewiring urea cycle metabolism in cancer to support anabolism. *Nat. Rev. Cancer* **2018**, *18*, 634–645. <https://doi.org/10.1038/s41568-018-0054-z>.

173. Rabinovich, S.; Adler, L.; Yizhak, K.; Sarver, A.; Silberman, A.; Agron, S.; Stettner, N.; Sun, Q.; Brandis, A.; Helbling, D.; et al. Diversion of aspartate in ASS1-deficient tumours fosters de novo pyrimidine synthesis. *Nature* **2015**, *527*, 379–383. <https://doi.org/10.1038/nature15529>.
174. Nagamani, S.C.; Erez, A. A metabolic link between the urea cycle and cancer cell proliferation. *Mol. Cell Oncol.* **2016**, *3*, e1127314. <https://doi.org/10.1080/23723556.2015.1127314>.
175. Khare, S.; Kim, L.C.; Lobel, G.; Doulias, P.-T.; Ischiropoulos, H.; Nissim, I.; Keith, B.; Simon, M.C. ASS1 and ASL suppress growth in clear cell renal cell carcinoma via altered nitrogen metabolism. *Cancer Metab.* **2021**, *9*, 40. <https://doi.org/10.1186/s40170-021-00271-8>.
176. Erez, A.; Nagamani, S.C.S.; A Shchelochkov, O.; Premkumar, M.H.; Campeau, P.; Chen, Y.; Garg, H.K.; Li, L.; Mian, A.; Bertin, T.K.; et al. Requirement of argininosuccinate lyase for systemic nitric oxide production. *Nat. Med.* **2011**, *17*, 1619–1626. <https://doi.org/10.1038/nm.2544>.
177. Qiu, F.; Chen, Y.-R.; Liu, X.; Chu, C.-Y.; Shen, L.-J.; Xu, J.; Gaur, S.; Forman, H.J.; Zhang, H.; Zheng, S.; et al. Arginine starvation impairs mitochondrial respiratory function in ASS1-deficient breast cancer cells. *Sci. Signal.* **2014**, *7*, ra31. <https://doi.org/10.1126/scisignal.2004761>.
178. Zhou, L.; Zhang, H.; Wu, J. Effects of nitric oxide on the biological behavior of HepG2 human hepatocellular carcinoma cells. *Exp. Ther. Med.* **2016**, *11*, 1875–1880. <https://doi.org/10.3892/etm.2016.3128>.
179. Keshet, R.; Erez, A. Arginine and the metabolic regulation of nitric oxide synthesis in cancer. *Dis. Model. Mech.* **2018**, *11*, dmm033332. <https://doi.org/10.1242/dmm.033332>.
180. Kobayashi, E.; Masuda, M.; Nakayama, R.; Ichikawa, H.; Satow, R.; Shitashige, M.; Honda, K.; Yamaguchi, U.; Shoji, A.; Tochigi, N.; et al. Reduced argininosuccinate synthetase is a predictive biomarker for the development of pulmonary metastasis in patients with osteosarcoma. *Mol. Cancer Ther.* **2010**, *9*, 535–544. <https://doi.org/10.1158/1535-7163.MCT-09-0774>.
181. Ochocki, J.D.; Khare, S.; Hess, M.; Ackerman, D.; Qiu, B.; Daisak, J.I.; Worth, A.J.; Lin, N.; Lee, P.; Xie, H.; et al. Arginase 2 suppresses renal carcinoma progression via biosynthetic cofactor pyridoxal phosphate depletion and increased polyamine toxicity. *Cell Metab.* **2018**, *27*, 1263–1280.e6. <https://doi.org/10.1016/j.cmet.2018.04.009>.
182. Polisenio, L.; Salmena, L.; Zhang, J.; Carver, B.; Haveman, W.J.; Pandolfi, P.P. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. *Nature* **2010**, *465*, 1033–1038. <https://doi.org/10.1038/nature09144>.
183. Monti, M.; Lunardini, S.; Magli, I.A.; Campi, R.; Primiceri, G.; Berardinelli, F.; Amparore, D.; Terracciano, D.; Lucarelli, G.; Schips, L.; et al. Micro-RNAs predict response to systemic treatments in metastatic renal cell carcinoma patients: Results from a systematic review of the literature. *Biomedicines* **2022**, *10*, 1287. <https://doi.org/10.3390/biomedicines10061287>.
184. Wang, K.; Sun, Y.; Guo, C.; Liu, T.; Fei, X.; Chang, C. Androgen receptor regulates ASS1P3/miR-34a-5p/ASS1 signaling to promote renal cell carcinoma cell growth. *Cell Death Dis.* **2019**, *10*, 339. <https://doi.org/10.1038/s41419-019-1330-x>.
185. Shi, X.-B.; Xue, L.; Ma, A.-H.; Tepper, C.G.; Gandour-Edwards, R.; Kung, H.-J.; White, R.W.D. Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells. *Oncogene* **2013**, *32*, 4130–4138. <https://doi.org/10.1038/onc.2012.425>.
186. Izumi, K.; Zheng, Y.; Li, Y.; Zaengle, J.; Miyamoto, H. Epidermal growth factor induces bladder cancer cell proliferation through activation of the androgen receptor. *Int. J. Oncol.* **2012**, *41*, 1587–1592. <https://doi.org/10.3892/ijo.2012.1593>.
187. Fujii, R.; Hanamura, T.; Suzuki, T.; Gohno, T.; Shibahara, Y.; Niwa, T.; Yamaguchi, Y.; Ohnuki, K.; Kakugawa, Y.; Hirakawa, H.; et al. Increased androgen receptor activity and cell proliferation in aromatase inhibitor-resistant breast carcinoma. *J. Steroid Biochem. Mol. Biol.* **2014**, *144 Pt. B*, 513–522. <https://doi.org/10.1016/j.jsbmb.2014.08.019>.
188. Zeng, J.; Li, Y.; Wang, Y.; Xie, G.; Feng, Q.; Yang, Y.; Feng, J. lncRNA 00312 attenuates cell proliferation and invasion and promotes apoptosis in renal cell carcinoma via miR-34a-5p/ASS1 axis. *Oxid. Med. Cell. Longev.* **2020**, *2020*, 5737289. <https://doi.org/10.1155/2020/5737289>.
189. di Meo, N.A.; Loizzo, D.; Pandolfo, S.D.; Autorino, R.; Ferro, M.; Porta, C.; Stella, A.; Bizzoca, C.; Vincenti, L.; Crocetto, F.; et al. Metabolomic approaches for detection and identification of biomarkers and altered pathways in bladder cancer. *Int. J. Mol. Sci.* **2022**, *23*, 4173. <https://doi.org/10.3390/ijms23084173>.
190. Lucarelli, G.; Loizzo, D.; Ferro, M.; Rutigliano, M.; Vartolomei, M.D.; Cantiello, F.; Buonerba, C.; Di Lorenzo, G.; Terracciano, D.; De Cobelli, O.; et al. Metabolomic profiling for the identification of novel diagnostic markers and therapeutic targets in prostate cancer: An update. *Exp. Rev. Mol. Diagn.* **2019**, *19*, 377–387. <https://doi.org/10.1080/14737159.2019.1604223>.
191. Papale, M.; Vocino, G.; Lucarelli, G.; Rutigliano, M.; Gigante, M.; Rocchetti, M.T.; Pesce, F.; Sanguedolce, F.; Bufo, P.; Battaglia, M.; et al. Urinary RKIP/p-RKIP is a potential diagnostic and prognostic marker of clear cell renal cell carcinoma. *Oncotarget* **2017**, *8*, 40412–40424. <https://doi.org/10.18632/oncotarget.16341>.
192. Lucarelli, G.; Rutigliano, M.; Sanguedolce, F.; Galleggiante, V.; Giglio, A.; Cagiano, S.; Bufo, P.; Maiorano, E.; Ribatti, D.; Ranieri, E.; et al. Increased expression of the autocrine motility factor is associated with poor prognosis in patients with clear cell-renal cell carcinoma. *Medicine* **2015**, *94*, e2117. <https://doi.org/10.1097/MD.0000000000002117>.
193. Gigante, M.; Lucarelli, G.; Divella, C.; Netti, G.S.; Pontrelli, P.; Cafiero, C.; Grandaliano, G.; Castellano, G.; Rutigliano, M.; Stallone, G.; et al. Soluble serum α Klotho Is a potential predictive marker of disease progression in clear cell renal cell carcinoma. *Medicine* **2015**, *94*, e1917. <https://doi.org/10.1097/MD.0000000000001917>.

194. Lucarelli, G.; Dittono, P.; Bettocchi, C.; Vavallo, A.; Rutigliano, M.; Galleggiante, V.; LaRocca, A.M.V.; Castellano, G.; Gesualdo, L.; Grandaliano, G.; et al. Diagnostic and prognostic role of preoperative circulating CA 15-3, CA 125, and beta-2 microglobulin in renal cell carcinoma. *Dis. Mark.* **2014**, *2014*, 689795. <https://doi.org/10.1155/2014/689795>.
195. Zhang, M.; Liu, X.; Liu, X.; Li, H.; Sun, W.; Zhang, Y. A pilot investigation of a urinary metabolic biomarker discovery in renal cell carcinoma. *Int. Urol. Nephrol.* **2020**, *52*, 437–446. <https://doi.org/10.1007/s11255-019-02332-w>.
196. Falegan, O.S.; Ball, M.W.; Shaykhtudinov, R.A.; Pieroraio, P.M.; Farshidfar, F.; Vogel, H.J.; Allaf, M.E.; Hyndman, M.E. Urine and serum metabolomics analyses may distinguish between stages of renal cell carcinoma. *Metabolites* **2017**, *7*, 6. <https://doi.org/10.3390/metabo7010006>.
197. Bifarin, O.O.; Gaul, D.A.; Sah, S.; Arnold, R.S.; Ogan, K.; Master, V.A.; Roberts, D.L.; Bergquist, S.H.; Petros, J.A.; Edison, A.S.; et al. Urine-based metabolomics and machine learning reveals metabolites associated with renal cell carcinoma stage. *Cancers* **2021**, *13*, 6253. <https://doi.org/10.3390/cancers13246253>.
198. Amaro, F.; Carvalho, M.; Bastos, M.L.; Guedes de Pinho, P.; Pinto, J. Pharmacometabolomics applied to personalized medicine in urological cancers. *Pharmaceuticals* **2022**, *15*, 295. <https://doi.org/10.3390/ph15030295>.
199. Sharma, R.; Kadife, E.; Myers, M.; Kannourakis, G.; Prithviraj, P.; Ahmed, N. Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma. *J. Exp. Clin. Cancer Res.* **2021**, *40*, 186. <https://doi.org/10.1186/s13046-021-01961-3>.
200. Escudier, B.; Porta, C.; Schmidinger, M.; Rioux-Leclercq, N.; Bex, A.; Khoo, V.; Grünwald, V.; Gillessen, S.; Horwich, A.; ESMO Guidelines Committee. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. *Ann. Oncol.* **2019**, *30*, 706–720. <https://doi.org/10.1093/annonc/mdz056>.
201. Kapoor, A. First-line treatment options in metastatic renal cell cancer. *Can. Urol. Assoc. J.* **2016**, *10* (Suppl. 7), S236–S238. <https://doi.org/10.5489/cuaj.4307>.
202. Netti, G.S.; Lucarelli, G.; Spadaccino, F.; Castellano, G.; Gigante, M.; Divella, C.; Rocchetti, M.T.; Rascio, F.; Mancini, V.; Stallone, G.; et al. PTX3 modulates the immunoflogosis in tumor microenvironment and is a prognostic factor for patients with clear cell renal cell carcinoma. *Aging* **2020**, *12*, 7585–7602. <https://doi.org/10.18632/aging.103169>.
203. Gigante, M.; Pontrelli, P.; Herr, W.; Gigante, M.; D’Avenia, M.; Zaza, G.; Cavalcanti, E.; Accetturo, M.; Lucarelli, G.; Carrieri, G.; et al. miR-29b and miR-198 overexpression in CD8⁺ T cells of renal cell carcinoma patients down-modulates JAK3 and MCL-1 leading to immune dysfunction. *J. Transl. Med.* **2016**, *14*, 84. <https://doi.org/10.1186/s12967-016-0841-9>.
204. De Marco, S.; Torsello, B.; Minutiello, E.; Morabito, I.; Grasselli, C.; Bombelli, S.; Zucchini, N.; Lucarelli, G.; Strada, G.; Perego, R.A.; et al. The cross-talk between Abl2 tyrosine kinase and TGFβ1 signalling modulates the invasion of clear cell renal cell carcinoma cells. *FEBS Lett.* **2022**, *ahead of print*. <https://doi.org/10.1002/1873-3468.14531>.
205. Motzer, R.J.; Tannir, N.M.; McDermott, D.F.; Aren Frontera, O.; Melichar, B.; Choueiri, T.K.; Plimack, E.R.; Barthélémy, P.; Porta, C.; George, S.; et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. *N. Engl. J. Med.* **2018**, *378*, 1277–1290. <https://doi.org/10.1056/NEJMoa1712126>.
206. Powles, T.; Plimack, E.R.; Soulières, D.; Waddell, T.; Stus, V.; Gafanov, R.; Nosov, D.; Pouliot, F.; Melichar, B.; Vynnychenko, I.; et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): Extended follow-up from a randomised, open-label, phase 3 trial. *Lancet Oncol.* **2020**, *21*, 1563–1573. Erratum in *Lancet Oncol.* **2020**, *21*, e553. [https://doi.org/10.1016/S1470-2045\(20\)30436-8](https://doi.org/10.1016/S1470-2045(20)30436-8).
207. Motzer, R.J.; Penkov, K.; Haanen, J.; Rini, B.; Albiges, L.; Campbell, M.T.; Venugopal, B.; Kollmannsberger, C.; Negrier, S.; Uemura, M.; et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. *N. Engl. J. Med.* **2019**, *380*, 1103–1115. <https://doi.org/10.1056/NEJMoa1816047>.
208. Xu, J.X.; Maher, V.E.; Zhang, L.; Tang, S.; Sridhara, R.; Ibrahim, A.; Kim, G.; Pazdur, R. FDA approval summary: Nivolumab in advanced renal cell carcinoma after anti-angiogenic therapy and exploratory predictive biomarker analysis. *Oncologist* **2017**, *22*, 311–317. <https://doi.org/10.1634/theoncologist.2016-0476>.
209. Hatakeyama, H.; Fujiwara, T.; Sato, H.; Terui, A.; Hisaka, A. Investigation of metabolomic changes in sunitinib-resistant human renal carcinoma 786-O cells by capillary electrophoresis-time of flight mass spectrometry. *Biol. Pharm. Bull.* **2018**, *41*, 619–627. <https://doi.org/10.1248/bpb.b17-00992>.
210. Sato, T.; Kawasaki, Y.; Maekawa, M.; Takasaki, S.; Morozumi, K.; Sato, M.; Shimada, S.; Kawamorita, N.; Yamashita, S.; Mitsuzuka, K.; et al. Metabolomic analysis to elucidate mechanisms of sunitinib resistance in renal cell carcinoma. *Metabolites* **2020**, *11*, 1. <https://doi.org/10.3390/metabo11010001>.
211. Mock, A.; Zschäbitz, S.; Kirsten, R.; Scheffler, M.; Wolf, B.; Herold-Mende, C.; Kramer, R.; Busch, E.; Jenzer, M.; Jäger, D.; et al. Serum very long-chain fatty acid-containing lipids predict response to immune checkpoint inhibitors in urological cancers. *Cancer Immunol. Immunother.* **2019**, *68*, 2005–2014. <https://doi.org/10.1007/s00262-019-02428-3>.
212. Jobard, E.; Blanc, E.; Négrier, S.; Escudier, B.; Gravis, G.; Chevreau, C.; Elena-Herrmann, B.; Trédan, O. A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma. *Br. J. Cancer* **2015**, *113*, 1148–1157. <https://doi.org/10.1038/bjc.2015.322>.
213. Li, H.; Bullock, K.; Gurjao, C.; Braun, D.; Shukla, S.A.; Bossé, D.; Lalani, A.-K.A.; Gopal, S.; Jin, C.; Horak, C.; et al. Metabolomic adaptations and correlates of survival to immune checkpoint blockade. *Nat. Commun.* **2019**, *10*, 4346. <https://doi.org/10.1038/s41467-019-12361-9>.

214. Deleuze, A.; Saout, J.; Dugay, F.; Peyronnet, B.; Mathieu, R.; Verhoest, G.; Bensalah, K.; Crouzet, L.; Laguerre, B.; Belaud-Rotureau, M.-A.; et al. Immunotherapy in renal cell carcinoma: The future is now. *Int. J. Mol. Sci.* **2020**, *21*, 2532. <https://doi.org/10.3390/ijms21072532>.
215. Bellmunt, J.; Szczylik, C.; Feingold, J.; Strahs, A.; Berkenblit, A. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. *Ann. Oncol.* **2008**, *19*, 1387–1392. <https://doi.org/10.1093/annonc/mdn066>.
216. Yao, Z.; Zheng, Z.; Zheng, X.; Wu, H.; Zhao, W.; Mu, X.; Sun, F.; Wu, K.; Zheng, J. Comprehensive characterization of metabolism-associated subtypes of renal cell carcinoma to aid clinical therapy. *Oxid. Med. Cell. Longev.* **2022**, *2022*, 9039732. <https://doi.org/10.1155/2022/9039732>.
217. Hoefflin, R.; Harlander, S.; Schäfer, S.; Metzger, P.; Kuo, F.; Schönenberger, D.; Adlesic, M.; Peighambari, A.; Seidel, P.; Chen, C.-Y.; et al. HIF-1 α and HIF-2 α differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice. *Nat. Commun.* **2020**, *11*, 4111. <https://doi.org/10.1038/s41467-020-17873-3>.
218. Wang, G.; Zhang, Z.-J.; Jian, W.-G.; Liu, P.-H.; Xue, W.; Wang, T.-D.; Meng, Y.-Y.; Yuan, C.; Li, H.-M.; Yu, Y.-P.; et al. Novel long noncoding RNA OTUD6B-AS1 indicates poor prognosis and inhibits clear cell renal cell carcinoma proliferation via the Wnt/ β -catenin signaling pathway. *Mol. Cancer* **2019**, *18*, 15. <https://doi.org/10.1186/s12943-019-0942-1>.
219. Accetturo, M.; D'Uggento, A.M.; Portincasa, P.; Stella, A. Improvement of MEFV gene variants classification to aid treatment decision making in familial Mediterranean fever. *Rheumatology* **2020**, *59*, 754–761. <https://doi.org/10.1093/rheumatology/kez332>.
220. Lucarelli, G.; Ferro, M.; Battaglia, M. Multi-omics approach reveals the secrets of metabolism of clear cell-renal cell carcinoma. *Transl. Androl. Urol.* **2016**, *5*, 801–803. <https://doi.org/10.21037/tau.2016.06.1>.
221. Lucarelli, G.; Rutigliano, M.; Loizzo, D.; di Meo, N.A.; Lasorsa, F.; Mastropasqua, M.; Maiorano, E.; Bizzoca, C.; Vincenti, L.; Battaglia, M.; et al. MUC1 tissue expression and its soluble form CA 15-3 identify a clear cell renal cell carcinoma with distinct metabolic profile and poor clinical outcome. *Int. J. Mol. Sci.* **2022**, *23*, 13968. <https://doi.org/10.3390/ijms232213968>.
222. Lucarelli, G.; Rutigliano, M.; Sallustio, F.; Ribatti, D.; Giglio, A.; Signorile, M.L.; Grossi, V.; Sanese, P.; Napoli, A.; Maiorano, E.; et al. Integrated multi-omics characterization reveals a distinctive metabolic signature and the role of NDUFA4L2 in promoting angiogenesis, chemoresistance, and mitochondrial dysfunction in clear cell renal cell carcinoma. *Aging* **2018**, *10*, 3957–3985. <https://doi.org/10.18632/aging.101685>.
223. Lippa, K.A.; Aristizabal-Henao, J.J.; Beger, R.D.; Bowden, J.A.; Broeckling, C.; Beecher, C.; Davis, W.C.; Dunn, W.B.; Flores, R.; Goodacre, R.; et al. Reference materials for MS-based untargeted metabolomics and lipidomics: A review by the metabolomics quality assurance and quality control consortium (mQACC). *Metabolomics* **2022**, *18*, 24. <https://doi.org/10.1007/s11306-021-01848-6>.